| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Amarin Corporation plc$14.46
+0.09 (+0.63%)
C 49Pipeline Score Fair Value Pharma · Commercial
Market Cap
303.58 M
EPS
-1.62
P/E Ratio
-8.93 $
Value Trade
732.59 K
SEC Financials
Q1 2026Dilution Risk
Revenue
45.13 M
R&D Expenses
4.67 M
Operating CF
6.39 M
Total Assets
645.76 M
Total Liabilities
196.35 M
Equity
449.41 M
D/E Ratio
12,345
-1.64 %
Week
-0.35 %
1 Month
-7.26 %
3 Month
-12.28 %
6 Month
-84.32 %
5 Year
-99.88 %
All Time
Cash Data
Cash Position
307.82 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
Apr 29, 2026
Overview
Volume
116.03 K
52 Week Range
11.65 - 20.90
% held by Insiders
0.41 %
% held by Institutions
21.97 %
Enterprise Value
1.14 M
Total Shares
20.98 M
Short %
2.6 %
Float Shares
20.89 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Amarin Corporation plc
831Total events
3Upcoming
179Tier-1 (high impact)
2010 – 2029Coverage
Upcoming catalysts 2
TBD
T1IP Litigation Ruling
Subscribe to view catalyst details
TBD
T1Partnership / License
Subscribe to view catalyst details
Event history 2
TBD
▲FDA ApprovalFDA Decision
Subscribe to view catalyst details
TBD
●Quarterly UpdateVASCEPAApprovedCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2025-03-29 | VASCEPA (icosapent ethyl) | Pre-clinical Data readout | Pre-clinical | — | – | – | – |
2025-03-29 | VASCEPA (icosapent ethyl) | Pre-clinical Data readout | Pre-clinical | — | – | – | – |
2025-03-29 | VASCEPA (icosapent ethyl) | Pre-clinical Data readout | Pre-clinical | — | – | – | – |
Drug Pipeline Intelligence
C49
Pipeline Score $471M
Pipeline ValueFair Value
Valuation Signal3
Drugs Scored1.6x
rNPV / MCap Top 74%
Micro Cap (rank 238 of 912)
Percentile RankAmarin Corporation plc carries a moderate pipeline score (49/100), with $2.4B risk-adjusted pipeline value, led by AMR101 - /day in Hypertriglyceridemia (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AMR101 - /day Small molecule | Hypertriglyceridemia | Phase 3 | NCT01047501 | 53% | $1.3B | COMPLETED | 931 | - | - | Feb 1, 2011 | - | Apr 25, 2022 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
icosapent ethyl | cardiovascular disease | — | 2026-05-27 | RW-apoB levels were on average calculated to be approximately 30% higher than measured apoB; Across 3,485 participants in the REDUCE-IT placebo arm followed for a median of 4.9 years Read More | New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia Read More | |
icosapent ethyl | cardiovascular disease | — | 2026-05-27 | RW-apoB levels were on average calculated to be approximately 30% higher than measured apoB; Across 3,485 participants in the REDUCE-IT placebo arm followed for a median of 4.9 years Read More | New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia Read More | |
icosapent ethyl | cardiovascular disease | — | 2026-05-27 | RW-apoB levels were on average calculated to be approximately 30% higher than measured apoB; Across 3,485 participants in the REDUCE-IT placebo arm followed for a median of 4.9 years Read More | New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in AMRN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
AMRN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
AMRN▲ +0.6%today
Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026
Amarin Corporation plc has announced it will report its second quarter 2026 financial results on July 29, 2026. A press release will be issued before the market opens, followed by a conference call at 8:00 a.m. ET. The call will be accessible via telephone and online, with a replay available after the event.
Read more →AMRNAmarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape
Amarin Corporation reaffirms the role of VASCEPA in managing severe hypertriglyceridemia amidst the recent FDA approval of injectable APOC3 therapies. CEO Aaron Berg highlights VASCEPA's proven efficacy, lower cost, and broad access compared to newer, more expensive options. The company emphasizes the importance of prioritizing established therapies like VASCEPA for patients at risk of cardiovascular events.
Read more →AMRNNew REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia
Amarin Corporation presented new findings from a post hoc analysis of the REDUCE-IT trial at the EAS Congress 2026. The analysis indicates that risk-weighted apolipoprotein B (RW-apoB) can more effectively identify residual cardiovascular risk in statin-treated patients with elevated triglycerides compared to traditional lipid markers. This suggests RW-apoB's potential for improving risk stratification in clinical practice.
Read more →AMRNAmarin Reports 2026 First Quarter Financial Results
Amarin Corporation reported a 7% increase in total revenue for Q1 2026, driven by higher international sales and positive cash flow for the second consecutive quarter. The company noted strong demand for its product VAZKEPA in Europe, supported by new industry guidelines endorsing Icosapent Ethyl for cardiovascular risk management. Despite a slight decline in European revenue, the overall performance reflects a positive trend under its new business model.
Read more →AMRNAmarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026
Amarin Corporation announced it will report its first quarter 2026 financial results on April 29, 2026. A press release will precede a conference call with senior management at 8:00 a.m. ET. The call will be accessible via telephone and online, with a replay available for later access.
Read more →AMRNAmerican College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction
Amarin Corporation highlighted key findings from the ACC Scientific Sessions 2026, emphasizing the role of icosapent ethyl (IPE) in managing elevated triglycerides and cardiovascular risk. The new ACC/AHA guidelines stress the need for complementary therapies beyond statins to address residual cardiovascular risk. Presentations at the event reinforced the efficacy of IPE in high-risk populations, while also noting limitations of current therapies.
Read more →AMRNAmarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline
Amarin Corporation has praised the updated 2026 ACC/AHA/Multisociety Dyslipidemia Guidelines, which recommend the use of icosapent ethyl in managing cardiovascular risk for patients with elevated triglycerides. These guidelines encourage a comprehensive approach to cardiovascular risk management, moving beyond just LDL-C levels. The inclusion of icosapent ethyl as a recommended adjunct therapy highlights its proven effectiveness in reducing cardiovascular events in high-risk patients. Amarin views this update as a significant advancement in patient care and a validation of their commitment to addressing cardiovascular health.
Read more →AMRNNew REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo
Amarin Corporation announced that new data from the REDUCE-IT study will be presented at the American College of Cardiology's Annual Scientific Session & Expo. The presentations will include a secondary analysis of the efficacy of icosapent ethyl in patients at extreme cardiovascular risk and mechanistic data on lipoprotein(a) oxidation. This highlights Amarin's commitment to addressing cardiovascular disease.
Read more →AMRNEffects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology
A recent post hoc analysis of the REDUCE-IT study published in the European Journal of Preventive Cardiology indicates that icosapent ethyl (IPE) significantly reduces total hospitalizations and days lost due to hospitalization and death among patients with cardiovascular disease or diabetes. The analysis involved 8,179 participants over five years, demonstrating the treatment's impact on patient-centered outcomes. Experts emphasize the importance of these findings for improving patients' quality of life.
Read more →AMRN▼ -9.5%on this newsshared move
Amarin Reports Fourth Quarter and Full Year 2025 Financial Results
Amarin Corporation reported its fourth quarter and full year 2025 financial results, highlighting a positive shift in operational efficiency and market positioning. The company maintained its U.S. market leadership for VASCEPA and established a long-term partnership for VAZKEPA in Europe. Despite a 21% decrease in total net revenue, significant cost savings and a return to positive cash flow were achieved.
Read more →AMRNThis American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease
Amarin Corporation emphasizes the urgent need to utilize existing, proven therapies to combat cardiovascular disease during American Heart Month. Despite advancements, many patients remain untreated or undertreated, contributing to high rates of cardiovascular events. The company calls for a recommitment to data-driven care to address these gaps and save lives now.
Read more →AMRNAmarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026
Amarin Corporation plc has announced it will report its fourth quarter and full year 2025 financial results on February 25, 2026. The company will issue a press release in the pre-market hours, followed by a conference call at 8:00 a.m. ET. Investors can participate via telephone or online, with replay options available afterward.
Read more →AMRNAmarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization
Amarin Corporation highlights advancements in therapies for patients with elevated triglycerides, particularly emphasizing the role of its VASCEPA/VAZKEPA products. These therapies are expected to enhance patient access and treatment strategies, especially through payor-driven step therapy programs. VASCEPA has shown significant efficacy in reducing cardiovascular events and is approved in multiple countries.
Read more →AMRN▲ +16.9%on this newsshared move
AMARIN ANNOUNCES PRELIMINARY 2025 FINANCIAL HIGHLIGHTS AND OPERATIONAL ACCOMPLISHMENTS, INCLUDING ACHIEVING POSITIVE CASH FLOW; COMPANY WELL POSITIONED TO CAPTURE GLOBAL GROWTH OPPORTUNITIES U.S. IPE Market Leadership Su
Amarin Corporation announced preliminary financial highlights for 2025, reporting a positive cash flow achieved in Q4 ahead of expectations. The company successfully transitioned to a fully partnered model for global commercialization of VAZKEPA. They maintained a leading market position in the U.S. and realized substantial operational cost savings from their restructuring plan. Amarin's strong cash position and strategic initiatives are expected to support sustainable growth in the upcoming year.
Read more →AMRNNew REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients
Amarin Corporation presented a new post hoc analysis from the REDUCE-IT study at the AHA Scientific Sessions 2025, demonstrating that icosapent ethyl significantly reduces cardiovascular events in high-risk patients, regardless of aspirin use. This reinforces the drug's role in managing cardiovascular risk alongside statin therapy. The analysis follows an FDA update on fibrates, emphasizing the need for effective treatment options.
Read more →AMRNAmarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025
Amarin Corporation announced it will present new analyses at the AHA Scientific Sessions 2025, showcasing the efficacy of VASCEPA in reducing cardiovascular risk. The data will include findings from the REDUCE-IT study and mechanistic studies on Eicosapentaenoic Acid (EPA). This presentation aims to further establish VASCEPA's role in cardiovascular care.
Read more →AMRN▼ -11.2%on this newsshared move
Amarin Reports Third Quarter 2025 Financial Results
Amarin Corporation reported its Q3 2025 financial results, showcasing a successful transition to a fully partnered commercialization model across international markets. The company experienced a 17% increase in total net revenue compared to Q3 2024, driven by higher U.S. sales. Operating expenses decreased significantly, reflecting the benefits of a global reorganization. Amarin aims for sustainable positive free cash flow by 2026.
Read more →AMRNAmarin Issues Statement Supporting FDA’s Action to Revise Labeling for Fenofibrate Drugs Reinforcing a Lack of Cardiovascular Benefit
Amarin Corporation has expressed strong support for the FDA's recent decision to revise the labeling for fenofibrate drugs, emphasizing the lack of cardiovascular benefits associated with these medications. The updated labeling aims to encourage healthcare providers to prioritize clinically proven therapies for cardiovascular risk reduction. Amarin advocates for the use of its product, VASCEPA, as a more effective alternative for patients at risk of cardiovascular events.
Read more →AMRNAmarin to Report Third Quarter 2025 Financial Results and Host Conference Call on October 29, 2025
Amarin Corporation plc has announced it will report its third quarter 2025 financial results on October 29, 2025. The company will issue a press release before the market opens and host a conference call with senior management at 8:00 a.m. ET. Participation details for the call and replay options have been provided.
Read more →AMRNAmarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress
Amarin Corporation, in partnership with HLS Therapeutics, will present new scientific data at the Canadian Cardiovascular Congress (CCC) from October 23-26, 2025. The presentations will focus on the clinical benefits of Icosapent Ethyl (IPE) and the mechanistic effects of Eicosapentaenoic Acid (EPA) on cardiovascular health. This collaboration underscores their commitment to advancing cardiovascular care.
Read more →AMRNAmarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025
Amarin Corporation presented new in vitro data at the ESC Congress 2025, showcasing the effects of eicosapentaenoic acid (EPA) on lipoprotein(a) oxidation and its anti-inflammatory mechanisms. The findings suggest that EPA may reduce cardiovascular risk beyond triglyceride lowering, particularly in patients with elevated Lp(a). This research advances the understanding of EPA's role in managing atherosclerotic cardiovascular disease.
Read more →AMRNNew REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups
Amarin Corporation presented new analyses from the REDUCE-IT trial at the ESC Congress 2025, highlighting the benefits of VASCEPA/VAZKEPA (icosapent ethyl) in reducing cardiovascular disease risk in high-risk patient subgroups. The findings indicate significant reductions in total hospitalizations and cardiovascular events, reinforcing the therapy's role in managing complex conditions like cardiovascular-kidney-metabolic syndrome. The ESC/EAS Dyslipidemias Guideline reaffirmed high-dose icosapent ethyl as a recommended treatment for patients with elevated triglyceride levels.
Read more →AMRNNew Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025
Amarin Corporation announced that new analyses from the REDUCE-IT trial and mechanistic studies of icosapent ethyl (IPE) will be presented at the ESC Congress 2025. These presentations aim to highlight IPE's multifaceted cardioprotective effects, including its role in reducing cardiovascular risk and hospitalization duration. The findings are expected to deepen the understanding of IPE's mechanisms in cardiovascular care.
Read more →AMRNAmarin Reports Second Quarter 2025 Financial Results -- European Partnership with Recordati Established to Maximize VAZKEPA in Europe; Global Corporate Restructuring Implemented with Anticipated $70 Million in Operating
Amarin Corporation plc has announced its financial results for Q2 2025, highlighting a partnership with Recordati to boost the commercialization of VAZKEPA in Europe. The company is implementing a global restructuring aimed at saving $70 million in operating expenses within the next year. While total net revenue increased by 8% compared to the previous year, the company reported a net loss of $14.1 million, primarily due to significant restructuring charges. Overall, Amarin remains optimistic about its strategic directions and growth prospects in international markets.
Read more →AMRNAmarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025
Amarin Corporation plc has announced it will host a conference call on July 30, 2025, to discuss its financial results for the second quarter of 2025. The conference will include remarks from President & CEO Aaron Berg and senior management, following the release of the financial results in the pre-market hours. The call is part of Amarin's commitment to maintaining open communication with investors and enhancing understanding of its advancements in managing cardiovascular disease.
Read more →AMRN▲ +27.3%on this news
AMARIN ANNOUNCES EXCLUSIVE LICENSE AND SUPPLY AGREEMENT WITH RECORDATI TO COMMERCIALIZE VAZKEPA (ICOSAPENT ETHYL) IN EUROPE -- Company to Streamline Global Operations, Resulting in Approximately $70 Million of Cost Savin
Amarin Corporation has entered an exclusive licensing and supply agreement with Recordati to commercialize VAZKEPA (icosapent ethyl) across 59 European countries. This partnership is intended to leverage Recordati's expertise in the cardiovascular space while optimizing Amarin's global operations, leading to projected cost savings of approximately $70 million over the next year. The deal also includes upfront cash and milestone payments that could total up to $150 million based on sales performance. Amarin anticipates that this agreement will accelerate their path to positive cash flow.
Read more →AMRNAmarin Reports First Quarter 2025 Financial Results -- First Quarter 2025 Performance Reflects Contribution from Multiple Revenue Streams Across Geographies, Efforts to Support Strong Balance Sheet and Continued Strategi
Amarin Corporation plc reported its financial results for the first quarter of 2025, showcasing a revenue generation of $42 million, which reflects a 26% decrease from the previous year. Despite this decline, the company highlighted a notable increase in the market demand for its product VAZKEPA in Europe, with significant gains in various regions. Additionally, Amarin announced its successful compliance with Nasdaq listing requirements after implementing a 1-for-20 ADS ratio change. The management emphasized its commitment to maximizing the value of its products while maintaining a strong financial position.
Read more →AMRNAmarin Regains Compliance with Nasdaq Minimum Bid Price Requirement -- Nasdaq Compliance Follows ADS Ratio Change to Secure Company's Public Listing -- -- Amarin Remains Focused on Maximizing the Global Value of VASCEPA/
Amarin Corporation plc has announced that it has regained compliance with Nasdaq's minimum bid price requirement after maintaining an average share price of at least $1.00 for ten consecutive business days. This compliance confirmation, received on April 29, 2025, allows Amarin to continue trading on the Nasdaq Capital Market. The CEO highlighted this achievement as a significant step for the company, reaffirming its commitment to maximizing the global value of its product, VASCEPA/VAZKEPA, for patients at risk of cardiovascular disease.
Read more →AMRNAmarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025
Amarin Corporation plc has announced a conference call to discuss its financial results for the first quarter of 2025. The call will take place on May 7, 2025, at 8:00 a.m. ET, following the pre-market release of the financial results. Led by President & CEO Aaron Berg, the call will include a Q&A session for stakeholders to engage with the senior management team. Amarin emphasizes its commitment to advancing cardiovascular disease treatment and communicating effectively with investors.
Read more →AMRN▲ +6.6%on this news
Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change -- Action Taken to Maintain Company's Nasdaq Listing – DUBLIN, Ireland and BRIDGEWATER, N.J.
Amarin Corporation has announced an effective date of April 11, 2025, for a 1-for-20 ratio change of its American Depositary Shares (ADS) to comply with Nasdaq's minimum bid price requirement. This decision aims to enhance the per share market price of its ADSs, thereby maintaining the company's listing on The Nasdaq Capital Market. While the transition process will occur automatically for most ADS holders, there are uncertainties regarding the future trading prices post-change.
Read more →AMRNAmarin Appoints JEC Capital Partners' Michael Torok to Board of Directors DUBLIN, Ireland and BRIDGEWATER, N.J.
Amarin Corporation has appointed Michael Torok, Co-Founder and Managing Director of JEC Capital Partners, to its Board of Directors, effective immediately. The board anticipates that Torok's financial expertise and experience in governance will contribute to the company's objectives to enhance shareholder value. Torok expressed his eagerness to collaborate with the board and management to achieve strategic goals. His professional background includes roles in finance, corporate governance, and portfolio management.
Read more →AMRNAmarin Highlights Recent Data Presented at ACC.25 Evaluating Mechanistic Effects of Eicosapentaenoic Acid (EPA) in Lp(a)-Enriched Plasma and in Combination with GLP-1 Agonist
Amarin Corporation recently showcased key data regarding the effects of eicosapentaenoic acid (EPA) on lipoprotein(a) and its combination with GLP-1 receptor agonists during the ACC.25 conference. The data indicated that EPA significantly inhibits the oxidation of Lp(a)-enriched plasma, potentially enhancing cardiovascular risk management. Furthermore, the combination of EPA and liraglutide demonstrated beneficial effects on detoxification proteins in endothelial cells, suggesting a possible additive impact in reducing cardiovascular risk. The findings are expected to advance understanding and treatment of cardiovascular risks, particularly in high-risk patients.
Read more →AMRN▼ -14.9%on this news
Amarin Announces Plan to Initiate a Ratio Change Under Its American Depository Receipt (ADR) Program
Amarin Corporation has announced its intention to implement a ratio change for its American Depositary Shares (ADS) from 1:1 to 1:20. This change, effective around April 11, 2025, aims to increase the per share market price of the ADS to meet Nasdaq's minimum bid price requirement. Although the ordinary shares remain unaffected, existing ADS holders will see adjustments made automatically for uncertificated shares, while certificated holders will need to exchange their shares. However, the company warns there are no assurances regarding the trading price post-ratio change.
Read more →AMRN▼ -14.9%on this news
Amarin Reports Fourth Quarter Financial Results & Business Update and Announces Important Corporate Action -- Company Reports Fourth Quarter 2024 Total Revenues of $62.3 Million, Operating Expenses of $43.0 Million and Y
Amarin Corporation plc reported its fourth quarter financial results for 2024, revealing total revenues of $62.3 million and operating expenses of $43.0 million. The company highlighted strategic advancements in its commercialization efforts for VASCEPA/VAZKEPA, notably securing access in several international markets, including Italy and Australia. However, total net revenue saw a significant decline of 17% compared to the previous year, attributed to increased generic competition and lower sales volumes. Additionally, the company announced a 1-for-20 change to its ADS ratio aimed at maintaining its Nasdaq listing and long-term access to equity markets.
Read more →AMRNAmarin Marks Key Milestone for VASCEPA /VAZKEPA (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering
Amarin Corporation has announced a significant milestone with the publication of a post-hoc analysis from the REDUCE-IT study in the Journal of the American Heart Association. The findings demonstrate that icosapent ethyl (IPE), marketed as VASCEPA, reduced composite cardiovascular events by 34% in patients with well-controlled low-density lipoprotein cholesterol (LDL-C <55 mg/dL). This analysis highlights the potential of IPE as a complementary therapy alongside statins, reinforcing its role in improving cardiovascular health among high-risk patients. The robust results may influence future treatment guidelines for managing cardiovascular risk.
Read more →AMRNAmarin Receives National Reimbursement for VAZKEPA in Austria
Amarin Corporation announced that Austria's Health Authorities have approved its drug VAZKEPA for national reimbursement, aimed at reducing the risk of cardiovascular events in eligible adult patients. This approval becomes effective on April 1, 2025, marking the 10th national reimbursement of VAZKEPA in Europe. With cardiovascular diseases being the leading cause of death in Austria, the reimbursement is expected to alleviate healthcare burdens and improve patient outcomes. Amarin's CEO, Aaron Berg, expressed optimism for future growth as the company expands its market reach in Europe with VAZKEPA.
Read more →AMRNAmarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025
Amarin Corporation plc has announced a conference call scheduled for March 12, 2025, at 8:00 a.m. ET, to discuss its fourth quarter and full year 2024 financial results. The call will be led by President & CEO Aaron Berg and senior management. This event follows the release of the financial results during pre-market hours on the same day, and will be accessible via the company's investor relations website. The call aims to foster communication and transparency with investors and the public regarding Amarin's progress and strategies.
Read more →AMRNAmarin Receives National Reimbursement for VAZKEPA in Italy
Amarin Corporation announced that Italy's National Health Service has approved VAZKEPA (icosapent ethyl) for national reimbursement aimed at reducing cardiovascular risk in eligible high-risk patients. This notable development marks Italy as the third EU5 country to grant such reimbursement, as well as the ninth across Europe. The approval emphasizes the company's progress with its new strategic approach introduced in 2023, which has led to increased patient access in over 50% of the total established cardiovascular disease population in Western Europe. Additionally, the company's patent protection for VAZKEPA has been extended until 2039.
Read more →AMRNAMARIN APPOINTS PETER FISHMAN CHIEF FINANCIAL OFFICER -- Fishman Previously Served as Global Controller and Principal Financial & Accounting Officer for the Company -- DUBLIN, Ireland and BRIDGEWATER, N.J.
Amarin Corporation has appointed Peter Fishman as its new Chief Financial Officer, effective immediately. Fishman, who previously served as the Global Controller and principal financial and accounting officer, brings nearly 20 years of extensive finance experience to his new role. He will oversee Amarin's global finance organization and report directly to CEO Aaron Berg, who expressed confidence in Fishman's ability to support the company’s financial strategy moving forward. Fishman’s past contributions include playing a key role in the company’s financing efforts and current cash management initiatives.
Read more →AMRNAmarin Reports Third Quarter 2024 Financial Results and Provides Business Update -- Strong Cash Position of $306 Million; 9 th Consecutive Quarter of Positive or Neutral Cash Balance -- -- Total Net Revenue of $42 Millio
Amarin Corporation reported its financial results for Q3 2024, highlighting strong cash reserves of $306 million and continued revenue generation from its product VASCEPA/VAZKEPA. Notably, there was a 19% sequential growth in sales across Europe, particularly in Spain and the UK. However, the company faced challenges with a 36% decline in total net revenue compared to the previous year, primarily due to increased generic competition and loss of CVS exclusivity. The company plans a virtual analyst day on November 14 to discuss future strategies and opportunities.
Read more →AMRNAmarin Announces Two Upcoming Investor Events
Amarin Corporation plc has announced two significant upcoming events for investors. The company will report its financial results for the third quarter of 2024 on October 30, followed by a conference call. Additionally, Amarin will host a Virtual Analyst & Investor Day on November 14, aimed at updating stakeholders on the VASCEPA/VAZKEPA franchise and its future value, particularly in European markets.
Read more →AMRN▼ -12.9%on this news
Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update -- Cash Position of $307 Million Provides Stable and Strong Capital Foundation -- -- Total Net Revenue of $68 Million ($124 Million Year-T
Amarin Corporation reported its second quarter financial results for 2024, showing a total net revenue of $67.5 million, a decline from $80.2 million in the same period last year. The company maintains a strong cash position of $307 million and has successfully transitioned its leadership with Aaron Berg appointed as CEO. Several international developments, including regulatory approvals in China and reimbursement agreements in Europe, were highlighted, even as the U.S. market faces challenges. The company continues to focus on cost efficiency and revenue generation despite setbacks in product revenues due to generic competition.
Read more →AMRNAmarin Receives National Reimbursement for VAZKEPA (icosapent ethyl) in Portugal
Amarin Corporation announced that the Portuguese Ministry of Health has approved VAZKEPA (icosapent ethyl) for national reimbursement to mitigate cardiovascular event risks in high-risk statin-treated patients. This marks the eighth national reimbursement approval in Europe, indicating a growing recognition of the drug's value in addressing cardiovascular health. VAZKEPA is set to be commercially available in Portugal starting August 1, 2024, following the approval. Statistics reveal a significant incidence of cardiovascular disease in Portugal, thus emphasizing the urgent need for this treatment option.
Read more →AMRNAmarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024
Amarin Corporation plc has announced that it will report its second quarter 2024 financial results on July 31, 2024. The earnings call will feature President & CEO Aaron Berg and other senior management members, and shareholders can submit questions in advance. This initiative aims to enhance engagement between the company and its investors, reflecting Amarin's commitment to transparency and communication.
Read more →AMRNAmarin Partner EddingPharm Receives Regulatory Approval for VASCEPA (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)
Amarin Corporation's partner, EddingPharm, has secured regulatory approval for VASCEPA (icosapent ethyl) from China's National Medical Products Administration (NMPA). The drug is approved for reducing cardiovascular events in adults with high triglycerides and established cardiovascular disease or diabetes. EddingPharm is set to work on including VASCEPA in the National Reimbursement Drug Listing, enhancing its commercial launch across China. Amarin stands to gain a $15 million regulatory milestone payment following this approval.
Read more →AMRN▼ -17.9%on this news
AMARIN BOARD OF DIRECTORS ANNOUNCES CEO TRANSITION -- Board Appoints Aaron Berg as President & CEO -- -- Patrick Holt to Step Down as President & CEO to Pursue Other Opportunities -- DUBLIN, Ireland and BRIDGEWATER, N.J.
Amarin Corporation has announced a leadership transition, appointing Aaron Berg as the new President and CEO, following Patrick Holt's resignation. Berg brings over 30 years of experience in the biopharmaceutical sector, having served in various roles within Amarin since 2012. His focus will be on maximizing the potential of VASCEPA and delivering value for investors. The Board expressed gratitude for Holt's contributions while highlighting confidence in Berg's ability to steer the company forward.
Read more →AMRNAmarin Receives National Reimbursement for VAZKEPA (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.
Amarin Corporation has announced that the Greek Ministry of Health has approved VAZKEPA (icosapent ethyl) for national reimbursement to help high-risk patients reduce cardiovascular events. This approval is significant as it marks the seventh such reimbursement of VAZKEPA in Europe. Additionally, Amarin has entered an exclusive commercialization agreement with Vianex S.A., which will handle the distribution and marketing of VAZKEPA in Greece. The partnership aims to leverage Vianex's extensive experience in the pharmaceutical sector to improve patient access to this treatment.
Read more →AMRN▲ +7.7%on this news
Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference
Amarin Corporation plc is set to participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference on May 20, 2024, where CEO Patrick Holt will engage in a fireside chat. This event will be webcasted live and also archived for later viewing. Amarin emphasizes its commitment to innovative cardiovascular disease management and scientific research. The company is actively expanding its commercial presence and communication with investors through various channels.
Read more →AMRN▼ -8.9%on this newsshared move
Amarin Reports First Quarter 2024 Business Update and Financial Results -- New VAZKEPA Patent Issued by European Patent Office Extends Intellectual Property Protection in Europe Until 2039 -- -- In Europe, ~35% Revenue G
Amarin Corporation plc reported a business update and financial results for Q1 2024, highlighting a new patent for VAZKEPA that extends exclusivity until 2039. The company experienced significant sales growth in Europe, with a 65% increase in sales driven by Spain and the UK. However, U.S. revenue fell by 41% due to pressure from generic competition. Amarin maintains a stable cash position and has a shareholder-approved share repurchase program expected to begin soon.
Read more →AMRNAmarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event
Amarin Corporation has endorsed a petition from HealthyWomen that urges the FDA to take action against the off-label use of fenofibrates in patients at risk of cardiovascular events. The petition highlights clinical studies demonstrating the lack of benefit from using fenofibrates in combination with statins, a concern that has persisted despite prior FDA mandates. Amarin emphasizes the importance of ensuring that patients receive effective, FDA-approved therapies, as cardiovascular disease remains a leading cause of mortality in the United States. The petition seeks to update fenofibrate labeling to inform healthcare professionals and patients about the ineffectiveness of the drug for reducing cardiovascular disease risk.
Read more →AMRNAmarin Announces Results of Annual General Meeting of Shareholders
Amarin Corporation plc announced that during its 2024 Annual General Meeting, shareholders approved all proposed resolutions including a significant share repurchase program of up to $50 million. This program allows the company to seek approval from the U.K. High Court to initiate buybacks by the end of Q2 2024. Other resolutions included re-election of board members, approval of executive compensation, and appointment of auditors. The chairman expressed gratitude toward shareholders for their engagement during the voting process.
Read more →AMRNAmarin Announces Results of Annual General Meeting of Shareholders - Shareholders Approve Share Repurchase Program of up to $50 Million - DUBLIN, Ireland and BRIDGEWATER, N.J.
Amarin Corporation plc has announced that its shareholders approved all resolutions from the 2024 Annual General Meeting, including a significant share repurchase program of up to $50 million. This approval allows the company to seek High Court approval in the U.K. and aims to initiate share repurchases by the end of Q2 2024. Furthermore, shareholders re-elected key directors and approved executive compensation, highlighting their support for the company's governance.
Read more →AMRNAmarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024
Amarin Corporation plc will report its first quarter 2024 financial results and hold a conference call on May 1, 2024, at 8:00 a.m. ET. The call will feature CEO Patrick Holt and other senior management. To foster engagement, Amarin is collaborating with Say Technologies allowing shareholders to submit questions for the management team. This initiative reflects Amarin's commitment to transparency and investor relations as it continues to expand in cardiovascular disease management.
Read more →AMRNAmarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24
Amarin Corporation presented essential data at ACC.24 highlighting the mechanistic activity of Eicosapentaenoic acid (EPA) and its effects on cardiovascular health. Key findings showed that EPA combined with statins may improve endothelial cell function and Lp(a) levels, potentially leading to a reduction in cardiovascular events for at-risk patients. The studies provide valuable insights into how EPA can positively influence cardiovascular disease management. Amarin's commitment to advancing the understanding and treatment of cardiovascular risk is further emphasized through these presentations.
Read more →AMRN▲ +7.1%on this newsshared move
Amarin Provides Update on VAZKEPA (Icosapent Ethyl) Intellectual Property Portfolio in Europe - Company's IP Protection for VAZKEPA in Europe Now Extended Into 2039 - DUBLIN, Ireland and BRIDGEWATER, N.J.
Amarin Corporation plc announced an extension of its intellectual property protection for VAZKEPA (icosapent ethyl) in Europe, which will now last until 2039. The European Patent Office granted a new patent and Amarin successfully defended a separate patent against opposition. These developments collectively enhance the product's market exclusivity, potentially increasing its impact on patients with cardiovascular issues. The announcement reflects Amarin's commitment to reinforcing its intellectual property rights and expanding its market position in Europe.
Read more →AMRN▼ -18.9%on this news
Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update -- Company Delivers Total Revenues of $75 Million in the Fourth Quarter and $306 Million for the Full-Year 2023 -- -- Reaffi
Amarin Corporation plc reported its financial results for Q4 and the full year 2023, revealing total revenues of $75 million for the quarter and $306 million for the year. The company has reaffirmed a cash position of $321 million and plans to initiate a $50 million share repurchase program. However, the company experienced a drop in net product revenue by 21% compared to the same quarter in the previous year, contributing to a net loss of $5.8 million in Q4 2023. The decrease was mainly attributed to reduced sales of VASCEPA in the U.S., impacted by generic competition.
Read more →AMRNAmarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024
Amarin Corporation plc has announced that it will hold a conference call on February 29, 2024, to present its financial results for the fourth quarter and full year of 2023. The call will feature remarks from Patrick Holt, President & CEO, and provide an opportunity for shareholders to engage by submitting questions. This initiative aims to enhance communication between management and investors while highlighting the company's progress in cardiovascular disease management.
Read more →AMRN▲ +9.5%on this news· ran to +20% by day 3
Amarin Chairman & CEO Issue Letter to Shareholders
Amarin Corporation's leadership issued a letter to shareholders highlighting significant changes made during 2023, including management restructuring and financial discipline improvements. The company believes it is now in a stronger position, expressing confidence in its potential and announcing a $50 million share repurchase plan. Despite acknowledging shareholder disappointment in stock performance, the leadership emphasizes unrealized value and outlines strategic goals for the upcoming year. They aim to strengthen market share and expand access for their products across various regions.
Read more →AMRN▲ +32.9%on this news
AMARIN PROVIDES PRELIMINARY FOURTH QUARTER 2023 SELECTED FINANCIALS AND OUTLINES KEY PRIORITIES FOR 2024 -- Reported Unaudited Total Revenues of Between $72 Million - $74 Million in the Fourth Quarter of 2023 -- -- Compa
Amarin Corporation has released its preliminary financial results for the fourth quarter of 2023, reporting total revenues between $72 million and $74 million, driven by significant performance in the U.S. market. The company ended the year with a robust cash position of approximately $321 million and a positive cash flow of around $10 million. For 2024, Amarin has outlined key priorities, including revenue growth in Europe and maintaining its leadership in the IPE market in the U.S. Additionally, a share repurchase program of up to $50 million is planned, subject to shareholder approval.
Read more →AMRNAmarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Amarin Corporation plc is set to present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024. The company’s president and CEO, Patrick Holt, will discuss the advancements Amarin is making in cardiovascular disease management. The conference presentation will be available via live webcast and archived on Amarin's investor relations website. This participation underscores Amarin's ongoing dedication to addressing cardiovascular risk beyond traditional therapies.
Read more →AMRNAmarin Reports Third Quarter 2023 Financial Results -- Company Reported Total Net Revenues of $66 Million in the Third Quarter 2023 -- -- Delivered Positive Cash Flow of $8 Million in the Quarter, Marking Fifth Consecuti
Amarin Corporation plc reported financial results for Q3 2023, highlighting total net revenues of $66 million and positive cash flow of $8 million. The company maintains a robust cash position of $321 million, supported by ongoing market leadership of VASCEPA. Despite a 27% drop in year-over-year revenues due to generic competition, launch activities for VAZKEPA in European countries are progressing well, aided by new leadership. The company also faces challenges, including a recent negative reimbursement decision in Italy, but continues to explore strategies to maximize market access globally.
Read more →AMRNAMARIN APPOINTS JONATHAN PROVOOST EXECUTIVE VICE PRESIDENT, CHIEF LEGAL & COMPLIANCE OFFICER Provoost Brings More than 20 Years of Corporate Counsel Experience to Amarin | DUBLIN, Ireland and BRIDGEWATER, N.J., OCTOBER 3
Amarin Corporation has appointed Jonathan Provoost as the new Executive Vice President, Chief Legal & Compliance Officer, starting November 15. Provoost brings over 20 years of experience from his previous role at Tris Pharma and has held various legal positions across the pharmaceutical sector. He will play a critical role in shaping Amarin's legal and compliance strategies, supporting the company's priorities in cardiovascular disease management.
Read more →AMRNAmarin to Report Third Quarter 2023 Financial Results and Host Conference Call on November 1, 2023
Amarin Corporation plc has announced that it will report its third quarter 2023 financial results on November 1, 2023, at 8:00 a.m. ET. The company will host a conference call featuring its President and CEO, Patrick Holt, alongside other senior management members. To facilitate shareholder engagement, Amarin is collaborating with Say Technologies to enable shareholders to submit and vote on questions, which will be addressed during the call. This initiative aims to strengthen connections with both retail and institutional investors.
Read more →AMRNAmarin to Present at the 2023 Cantor Global Healthcare Conference
Amarin Corporation plc announced that its CEO, Patrick Holt, will participate in a fireside chat at the 2023 Cantor Global Healthcare Conference scheduled for September 26-28, 2023, in New York City. The session will be available via live webcast, which will also be archived for future access. The announcement emphasizes Amarin's ongoing commitment to advancing cardiovascular disease management and its rapid growth in the pharmaceutical sector. Investors and interested parties are encouraged to engage with the company’s investor relations materials for more information.
Read more →AMRNAmarin Provides Pricing & Reimbursement Updates for VAZKEPA (icosapent ethyl) in The Netherlands and Italy
Amarin Corporation has recently announced that its drug VAZKEPA (icosapent ethyl) has received national reimbursement approval in the Netherlands for patients with established cardiovascular disease. In contrast, Italy's AIFA has issued a negative decision regarding VAZKEPA reimbursement, despite a positive scientific assessment. Amarin is engaged in discussions with Italian authorities to seek a favorable pricing outcome and ensure patient access to VAZKEPA. The company continues to work on pricing strategies in various European markets.
Read more →AMRNAmarin And Neopharm Announce Exclusive Commercialization Agreement for VAZKEPA (Icosapent Ethyl) in Israel
Amarin Corporation and Neopharm Israel have announced an exclusive commercialization agreement for VAZKEPA (icosapent ethyl) in Israel, following its recent regulatory approval. This agreement aims to reduce cardiovascular event risks in high-risk statin-treated patients. Neopharm will serve as the sole distributor for VAZKEPA in this market, leveraging its expertise in cardiology. The partnership marks a significant step towards increasing patient access to this important therapeutic option in Israel.
Read more →AMRNAmarin Reports Second Quarter 2023 Financial Results -- Company Reported Total Net Revenues of $80 Million in Second Quarter 2023; Total Net Revenues Included Net Product Revenues of $65 Million, $15 Million in License a
Amarin Corporation reported its financial results for the second quarter of 2023, highlighting total net revenues of $80 million, including $65 million in product revenues. The company achieved a positive cash flow of $9 million and maintains a strong cash position of $313 million, aided by a comprehensive cost reduction plan aimed at saving $40 million over the next year. Furthermore, Amarin received a positive recommendation for VAZKEPA's reimbursement in Spain, although U.S. product net revenue saw a significant decline due to market competition.
Read more →AMRNAmarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa (Icosapent Ethyl) in Southeast Asia and South Korea
Amarin Corporation and Lotus Pharmaceuticals have formed an exclusive partnership to distribute and commercialize VAZKEPA (icosapent ethyl) across 10 countries, including South Korea and several ASEAN nations. This collaboration aims to expand access to an innovative treatment for cardiovascular risk. Amarin will receive an upfront payment and milestone payments, while Lotus will leverage its existing infrastructure to promote the drug in these markets, which contain a growing patient base in need of effective cardiovascular therapies.
Read more →AMRNAmarin Receives Positive Recommendation from Spanish Drug Pricing Committee for National Reimbursement of VAZKEPA (icosapent ethyl) in Spain
Amarin Corporation has received a positive recommendation for its drug VAZKEPA (icosapent ethyl) from Spain's Drug Pricing Committee, paving the way for national reimbursement. This decision follows extensive negotiations and is set to improve access for cardiovascular patients at high risk, with availability expected to start on September 1, 2023. The recommendation highlights the drug's potential to significantly reduce cardiovascular events, addressing a pressing health need in Spain. Amarin aims to enhance awareness and adoption of VAZKEPA in the Spanish market as part of its ongoing efforts in Europe.
Read more →AMRNAmarin Board of Directors Announces Executive Compensation Program for New President and CEO Patrick Holt
Amarin Corporation has introduced a new executive compensation program for its recently appointed President and CEO, Patrick Holt. The program ties the majority of his compensation to shareholder value, specifically through stock options contingent on achieving certain share price hurdles. Holt's commitment to purchase $300,000 worth of Amarin shares further underscores his confidence in the company. The board believes this structure will enhance shareholder alignment and support the company’s mission in cardiovascular disease management.
Read more →AMRN▲ +9.2%on this newsshared move
Amarin Appoints Patrick Holt as President and Chief Executive Officer
Amarin Corporation has appointed Patrick Holt as the new President and CEO, effective immediately. With over 25 years in the life sciences, Holt has significant experience in turnaround management, previously serving as president of Cordis. The board is optimistic about Holt's ability to enhance shareholder value and address the company's critical needs. Aaron Berg, who has filled the role on an interim basis, will continue with Amarin in a senior leadership position.
Read more →AMRN▲ +9.2%on this newsshared move
Amarin Implements Organizational Restructuring to Strengthen the Company While Driving Patient Access to VASCEPA /VAZKEPA Globally Focus on Gaining Access for European Patients in Remaining Geographies and Strategic Use
Amarin Corporation plc has announced an organizational restructuring aimed at enhancing shareholder value and driving patient access to its products, VASCEPA and VAZKEPA. The restructuring is expected to result in annual savings of approximately $40 million and follows a comprehensive review of the company's operations by its new Board and management. Despite generating revenue in the U.S. and maintaining a strong cash position, Amarin acknowledged ongoing challenges, including pricing pressure and slower-than-expected revenue in Europe. The company remains committed to leveraging strong clinical data to support its products in addressing significant cardiovascular risks among high-risk patients.
Read more →AMRNAmarin Announces Vascepa (Icosapent Ethyl) Approved to Reduce Cardiovascular Risk in the Kingdom of Saudi Arabia (KSA)
Amarin Corporation announced that its drug VASCEPA (icosapent ethyl) has received approval from the Saudi Food and Drug Authority for reducing cardiovascular risk in adults with elevated triglyceride levels. The approval positions VASCEPA as the first approved medication in Saudi Arabia for this purpose, which is critical given the high incidence of cardiovascular disease in the region. Amarin, alongside its commercialization partner Biologix, aims to increase the drug's accessibility to patients in Saudi Arabia. This development is seen as a significant step in Amarin’s strategy to broaden its market reach and enhance cardiovascular disease management worldwide.
Read more →AMRNAmarin to Present at Two Upcoming Investor Conferences
Amarin Corporation plc has announced that its Interim President and CEO, Aaron Berg, along with CFO Tom Reilly, will present at two significant investor conferences in June 2023. The presentations will take place at the Jefferies Healthcare Conference on June 7 and the Goldman Sachs Global Healthcare Conference on June 12. Both events will be webcast live and made available for later viewing on Amarin's website, highlighting the company's commitment to investor engagement and transparency in its evolving cardiac-focused initiatives.
Read more →AMRNAmarin Partner EddingPharm Receives Regulatory Approval for Vascepa (Icosapent Ethyl) in Mainland China
Amarin Corporation announced that its partner, EddingPharm, has received regulatory approval from China's National Medical Products Administration for VASCEPA (icosapent ethyl) as a treatment for severe hypertriglyceridemia. EddingPharm is now working towards preparing for the commercial launch of VASCEPA across mainland China, which is expected by the end of the year. The approval is significant given the high prevalence of cardiovascular disease in China, affecting millions. Additionally, EddingPharm aims to secure reimbursement for this product and advance regulatory submissions for further indications.
Read more →AMRNAmarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa /Vazkepa (Icosapent Ethyl) Reduction of Cardiovascular Events
Amarin Corporation has released new data on VASCEPA/VAZKEPA, showcasing its beneficial effects on coronary physiology and plaque progression. The findings, published in the European Heart Journal and presented at the American Heart Association's meeting, indicate that the drug significantly reduces plaque burden in statin-treated patients and improves fractional flow reserve values. Additionally, an animal study revealed the drug's effectiveness in reducing atheroma progression and related inflammatory markers. These studies provide crucial insights into the mechanisms behind the drug's cardiovascular benefits.
Read more →AMRNAmarin Reports First Quarter 2023 Financial Results and Provides Business Update -- Stable Revenue and Cash Position Due to Performance of U.S. Business and Savings from Operational Initiatives -- -- Early Progress in La
Amarin Corporation reported its Q1 2023 financial results, showing stable revenue in the U.S. despite a 9% decrease in total revenue from Q1 2022. The company's U.S. product net revenue was $82.3 million, while regulatory approvals for VAZKEPA were secured in New Zealand and Israel. Amarin has initiated early launches of VAZKEPA in European markets and is actively working on pricing and reimbursement negotiations. Despite an overall net loss, effective cost reduction strategies have led to a decrease in operating expenses, with cash reserves of $304.9 million.
Read more →AMRNAmarin to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023
Amarin Corporation plc announced that it will host a conference call on May 3, 2023, at 8:00 a.m. ET to discuss its first quarter 2023 financial results. The call will take place following the pre-market release of these results. Amarin emphasizes its commitment to advancing the treatment of cardiovascular disease through ongoing research and clinical trials. The company operates both in Ireland and the United States, showcasing its international presence and commercial partnerships.
Read more →AMRNAMARIN NAMES AARON BERG INTERIM PRESIDENT & CHIEF EXECUTIVE OFFICER AND ADDS OLIVER O'CONNOR TO COMPANY'S BOARD OF DIRECTORS DUBLIN, Ireland and BRIDGEWATER, N.J.
Amarin Corporation has appointed Aaron Berg as Interim President and CEO while Oliver O'Connor joins the Board of Directors. Berg, with over 25 years in the biopharmaceutical industry, aims to leverage his experience to optimize Amarin's operations and enhance the value of VASCEPA. O'Connor provides substantial expertise in government and policy, which Amarin hopes will help unlock the potential of its products outside the U.S. Both appointments are effective immediately, as the Board seeks a permanent CEO.
Read more →AMRNAmarin Announces VAZKEPA (Icosapent Ethyl) Approved by Israel's Ministry of Health
Amarin Corporation has announced that Israel's Ministry of Health has approved VAZKEPA (icosapent ethyl) for reducing the risk of cardiovascular events in adult patients with elevated triglycerides who are on statin therapy. This marks a significant regulatory milestone, as cardiovascular disease is a leading cause of death in Israel. Amarin is preparing for potential market entry and reimbursement strategies for VAZKEPA in Israel starting in 2024.
Read more →AMRNAmarin Announces Board Departures
Amarin Corporation has announced the immediate resignation of all seven independent non-Sarissa board members. This move aims to facilitate Sarissa's request for control following the 2023 Special Meeting of Shareholders where Sarissa's slate of directors received strong shareholder backing. The departing members expressed confidence in Amarin’s leadership and the company’s value potential, wishing the new directors success in enhancing shareholder value.
Read more →AMRNAmarin Highlights New Evidence of Therapeutic Value of EPA in Reducing Cardiovascular Events in At-Risk Patients Presented at ACC.23/WCC
Amarin Corporation has presented new in vitro data at ACC.23/WCC highlighting the therapeutic value of eicosapentaenoic acid (EPA) in lowering cardiovascular events for at-risk patients. The findings underscore EPA's antithrombotic mechanisms and antioxidant effects that could contribute to a reduction in ischemic events. Importantly, results from the REDUCE-IT trial reaffirm these benefits, showing significant risk reduction without a concomitant increase in bleeding rates. This research strengthens Amarin's commitment to improving cardiovascular disease management and reflects ongoing advancements in their therapeutic offerings.
Read more →AMRNAmarin Announces Board Departures DUBLIN, Ireland and
Amarin Corporation announced the immediate resignation of all seven independent board members following a shareholder meeting where Sarissa's slate of directors was strongly backed. The departing members expressed confidence in the company's value potential and management. Their exit aims to provide Sarissa control to potentially enhance shareholder value. Amarin emphasizes its commitment to evolving cardiovascular disease management through innovation.
Read more →AMRNAmarin Announces New REDUCE-IT Data at ACC.23/WCC Showing Benefit of VASCEPA /VAZKEPA (Icosapent Ethyl) in High-Risk Patients with a Recent Acute Coronary Syndrome Event
Amarin Corporation announced new post-hoc analysis data from the REDUCE-IT study showing that their product, VASCEPA/VAZKEPA (icosapent ethyl), significantly reduces the risk of ischemic events by 37% and 36% in patients with recent acute coronary syndrome (ACS). The study highlights the benefit of early initiation of treatment without increasing the risk of bleeding. These findings were presented at the ACC.23/WCC conference and build on existing evidence of the product's efficacy across various high-risk patient populations. Limitations of the study included that it was not powered for multiple subgroup analyses.
Read more →AMRNAmarin Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update -- Company Delivers Positive Free Cash Flow in Fourth Quarter 2022 Following U.S. Revenue Stabilization -- -- Previously Ann
Amarin Corporation plc announced its financial results for Q4 and the full year 2022, highlighting positive cash flow and revenue stabilization in the U.S. The company has made substantial progress in expanding its VAZKEPA brand across international markets, including six new regulatory approvals and significant pricing agreements in Europe. While total revenue saw a decline due to increased generic competition, Amarin is focused on cost savings and believes it can achieve significant revenue growth from its international strategy.
Read more →AMRN▲ +10.3%on this newsshared move
Amarin Announces Preliminary Voting Results Following 2023 General Meeting of Shareholders
Amarin Corporation plc announced preliminary voting results from its 2023 General Meeting of Shareholders, where shareholders voted to elect seven nominees from Sarissa and remove Per Wold-Olsen as Chairman. The Board will expand to 15 members and will appoint a new Chairman shortly. Although the management team expressed a desire for a different outcome, they remain committed to executing the company's strategy during this transitional period. Final results of the board election will be reported after certification.
Read more →AMRN▲ +10.3%on this newsshared move
Amarin and CSL Seqirus Announce Exclusive License and Distribution Agreement to Commercialize VAZKEPA (Icosapent Ethyl) in Australia and New Zealand
Amarin Corporation has announced an exclusive licensing and distribution agreement with CSL Seqirus for the commercialization of VAZKEPA (icosapent ethyl) in Australia and New Zealand. Under the agreement, CSL Seqirus will manage market access, reimbursement efforts, and distribution, while Amarin will benefit from upfront and milestone payments. This partnership is positioned to leverage CSL Seqirus’s expertise in successfully navigating pharmaceutical markets, aiming to expand VAZKEPA’s reach to patients with cardiovascular disease in the region. The deal highlights Amarin's ongoing strategy to enhance its global footprint in the pharmaceutical market.
Read more →AMRNAmarin Sets the Record Straight on Sarissa’s Latest Misstatements
Amarin Corporation has issued a statement refuting misstatements made by Sarissa regarding its management compensation plan and the timing of its approval. The company clarified that the compensation plan was authorized in February, following standard practices. Additionally, Amarin asserted that its CEO's equity grants include performance-based components and that the results of the upcoming General Meeting will be disclosed post-meeting, as per SEC guidelines. The company is focused on evolving into a global cardiometabolic player and enhancing treatment methods for cardiovascular risks.
Read more →AMRNAmarin Corporation to Present New Data Evaluating VASCEPA /VAZKEPA (Icosapent Ethyl) at ACC.23/WCC
Amarin Corporation has announced its plans to present new data at the ACC.23/WCC, focusing on the efficacy of VASCEPA/VAZKEPA (icosapent ethyl) in reducing cardiovascular events among at-risk patients. The cornerstone of the presentation is derived from the REDUCE-IT trial, highlighting the drug's benefits for patients recently experiencing acute coronary syndrome. Amarin's research aims to deepen understanding of the role of eicosapentaenoic acid in cardiovascular health, with discussions scheduled across multiple sessions throughout the conference from March 4-6, 2023.
Read more →AMRNAmarin to Present at Cowen's 43rd Annual Health Care Conference
Amarin Corporation plc announced its participation in the Cowen Annual Health Care Conference taking place from March 6 to March 8, 2023, in Boston. The company's president and CEO, Karim Mikhail, is scheduled to present on March 8 at 1:30 p.m. ET. This presentation underscores Amarin's commitment to advancing cardiovascular disease management through innovative therapies. The event will be available via live webcast and archived on the company's investor relations website for broader access.
Read more →AMRNAmarin to Report Fourth Quarter and Full Year 2022 Financial Results And Host Conference Call on March 1st, 2023
Amarin Corporation plc announced it will host a conference call on March 1st, 2023, to discuss its fourth quarter and full year 2022 financial results. The call will follow the release of the financial results in the pre-market hours and will be accessible via the company's website. Amarin emphasizes its commitment to advancing understanding and treatment of cardiovascular risks that go beyond traditional therapies.
Read more →AMRNAmarin Urges Shareholders to Vote “Against” Sarissa’s Harmful Proposals at Upcoming General Meeting – IT HAS NO PLAN, NO NEW IDEAS AND AN UNDERQUALIFIED SLATE
Amarin Corporation has urged its shareholders to vote against Sarissa's proposals in the upcoming General Meeting scheduled for February 28, 2023. The company's Board argues that Sarissa's attempt to remove existing leadership could harm shareholder value, as the current Board has made significant progress and possesses essential expertise in pricing and reimbursement negotiations. Independent advisory firms have endorsed Amarin's Board, emphasizing that Sarissa has failed to present a compelling rationale for their suggested changes. Amarin aims to solidify its future by maintaining its current governance structure.
Read more →AMRNAmarin Clearly and Definitively Instructed Registrar to Accept ALL Submitted Proxy Cards
Amarin Corporation has corrected misinformation regarding the acceptance of proxy cards for its upcoming General Meeting. The company stated that all submitted proxy cards, including those from Sarissa Capital Management, would be accepted, countering claims made by Sarissa. This clarification was supported by confirmation from the registrar involved in the proxy solicitation process. Amarin emphasizes its commitment to its shareholders and the integrity of the voting process.
Read more →AMRNAmarin Shareholders Invited to Webcast with Board and Management Team
Amarin Corporation has announced a live webcast with its Board of Directors and management team scheduled for February 14, 2023. During this event, the leadership will answer shareholder questions regarding the company's strategy and ongoing efforts to enhance operational and financial performance. Shareholders are encouraged to submit their questions in advance as part of their engagement in the forthcoming General Meeting set for February 28, 2023.
Read more →AMRNAmarin Mails Letter Highlighting Why Shareholders Should Vote on the WHITE Proxy Card “AGAINST” Sarissa’s Harmful Proposals
Amarin Corporation has mailed a letter to its shareholders urging them to vote against Sarissa's proposals in an upcoming General Meeting scheduled for February 28, 2023. The letter emphasizes the positive changes brought by Amarin's new board and management team, addressing Sarissa's alleged history of value destruction and misinformation. Amarin promotes its commitment to enhancing shareholder value through its current strategy and board expertise, emphasizing the importance of rejecting Sarissa's influence in decision-making.
Read more →AMRNAmarin Mails Letter to Shareholders Highlighting Sarissa’s Myths vs. The Facts
Amarin Corporation plc has mailed a letter to shareholders countering claims made by Sarissa Capital Management as the company approaches its General Meeting scheduled for February 28, 2023. The letter details Sarissa's alleged misinformation while emphasizing Amarin's commitment to improving the company's performance through new management and strategic initiatives. Amarin also reports significant progress in launching its product in Europe and substantial cost savings achieved recently.
Read more →AMRNAmarin Mails Letter to Shareholders Highlighting New Board and Superior Leadership
Amarin Corporation has mailed a letter to its shareholders urging them to vote against Sarissa Capital Management's proposals at the upcoming General Meeting on February 28, 2023. The company emphasizes the successful execution of its transformation plan under its newly refreshed Board, which includes important leadership changes that have led to significant operational and financial progress. Amarin highlights various achievements, including international regulatory approvals and effective cost savings, while expressing concern that Sarissa's slate of candidates lacks the required skills for Amarin's strategic needs.
Read more →AMRNAmarin Files Definitive Proxy Materials and Mails Letter to Shareholders
Amarin Corporation has filed definitive proxy materials and mailed a letter to shareholders urging them to vote against proposals from activist hedge fund Sarissa Capital Management. The company highlights its significant transformation over the past 18 months, including a new leadership team and strategic focus on geographic expansion and operational excellence. Amarin argues that Sarissa's board nominees are underqualified and that its current strategy is essential for maximizing shareholder value moving forward. The upcoming shareholder vote is scheduled for February 28, 2023.
Read more →AMRNAmarin to Present at SVB Securities Global Biopharma Conference
Amarin Corporation plc announced its participation at the SVB Securities Global Biopharma Conference scheduled for February 14, 2023. CEO Karim Mikhail will present at the event, which will be available for live webcast. The conference highlights Amarin's commitment to addressing cardiovascular disease and its rapid evolution in the biopharmaceutical industry.
Read more →AMRNAmarin Announces VAZKEPA (Icosapent Ethyl) Approved By Medsafe In New Zealand
Amarin Corporation has announced that Medsafe in New Zealand has granted approval for VAZKEPA (icosapent ethyl) to help reduce cardiovascular event risks in adult patients with high cardiovascular risk. This approval is part of Amarin's effort to address the significant cardiovascular disease issues in New Zealand, where an estimated 175,000 adults are affected. The approval represents the seventh regulatory approval for VAZKEPA in key international markets since 2022, and Amarin is now looking to partner for commercializing the treatment in New Zealand.
Read more →AMRNAmarin Responds to Inaccurate and Misleading Statement by Sarissa
Amarin Corporation responded to claims made by Sarissa Capital Management regarding the company's board refreshment and strategic direction. The company defended its comprehensive approach to board restructuring and highlighted its new management team's effect on growth, especially in European markets. Though concerned about Sarissa's involvement potentially disrupting progress, Amarin demonstrated positive momentum in market share retention and expansion efforts in Europe.
Read more →AMRN▲ +5.8%on this news
Amarin Comments on Sarissa’s Notice to Call a Special Meeting of Amarin Shareholders
Amarin Corporation has received a requisition from Sarissa Capital Management to convene a Special Meeting of Shareholders, and has confirmed that all shareholders can expect further announcements regarding the meeting date and voting record. In response, Amarin emphasized its significant progress and operational improvements over the past year, which includes Board refreshment and successful international regulatory outcomes. The company actively contests Sarissa's claims and expressed concerns that the proxy contest may negatively impact its strategic initiatives.
Read more →AMRN▲ +16.2%on this news· ran to +41% by day 3shared move
AMARIN PROVIDES PRELIMINARY FOURTH QUARTER AND FULL YEAR 2022 REVENUE AND CASH POSITION AND PRIORITIES FOR 2023 Company Delivers Fourth Consecutive Quarter of U.S. Revenue Stabilization, Positive Fourth Quarter Cash Flow
Amarin Corporation has reported preliminary revenue figures for the fourth quarter and full year of 2022, indicating stabilization in its U.S. revenue for VASCEPA for the fourth consecutive quarter. The company ended 2022 with around $310 million in cash, showcasing positive cash flow of about $4 million in the fourth quarter. Amarin's CEO emphasized the company's focus on becoming a major player in cardiometabolic health, with strategic priorities set for 2023, including expansion efforts and reimbursement progress in Europe.
Read more →AMRN▲ +16.2%on this news· ran to +41% by day 3shared move
Amarin Board of Directors Announces Appointment of Murray W. Stewart, DM FRCP. Dr. Stewart Brings More Than 30 Years of Cardiometabolic Academic and Industry Experience to Amarin s Board Ongoing Board Refreshment Program
Amarin Corporation plc has announced the appointment of Dr. Murray W. Stewart to its Board of Directors, enhancing the board's expertise with his extensive background in cardiometabolic research. This move is part of an ongoing board refreshment initiative, resulting in approximately 75% new independent directors over the past 12 months. Dr. Stewart's experience includes roles at GlaxoSmithKline and Rhythm Pharmaceuticals, which will aid Amarin's strategic focus on diversifying its product portfolio and expanding internationally.
Read more →AMRNAmarin to Present at the 41st Annual J.P. Morgan Healthcare Conference
DUBLIN, Ireland and BRIDGEWATER, N.J., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin’s president and chief executive officer, is scheduled to participate at the 41st Annual J.P. Morgan Healthcare Conference on Ja
Read more →AMRNAmarin Announces VAZKEPA (icosapent ethyl) Receives Regulatory Approval in Switzerland
-- Amarin Continuing Process for Obtaining National Pricing and Reimbursement in Switzerland in the Course of 2023 -- -- Swissmedic Approval Underpins Company’s Presence and Expansion in Switzerland as its Regional Commercial Hub for Europe -- DUBLIN, Ireland and BRIDGEWATER, N
Read more →AMRNForward Looking Statements & Disclaimer This presentation contains forward-looking statements, such as those relating to the commercial potential of VASCEPA (VAZKEPA in Europe), clinical and regulatory efforts and timeli
November Investor Presentation November 16, 2022 Karim Mikhail President & CEO Exhibit 99.1 Forward Looking Statements & Disclaimer This presentation contains forward-looking statements, such as those relating to the commercial potential of VASCEPA (VAZKEPA in Europe), clinica
Read more →AMRNAmarin Announces VAZKEPA (icosapent ethyl) Approved by the Therapeutic Goods Administration (TGA) in Australia
-- VAZKEPA® Approved in Australia to Reduce the Risk of CV Events in Adult Statin-Treated Patients with High CV Risk with Elevated Triglycerides -- -- Marks Fifth Regulatory Approval for VASCEPA®/VAZKEPA® Franchise in Key International Markets in 2022 -- DUBLIN, Ireland and BRI
Read more →AMRNAmarin to Present at Jefferies London Healthcare Conference
DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin’s president and chief executive officer, is scheduled to participate at the Jefferies London Healthcare Conference. Jefferies
Read more →AMRN▲ +12%on this newsshared move
Amarin Highlights Key Data Presented at American Heart Association 2022 Scientific Sessions for VASCEPA /VAZKEPA (icosapent ethyl) and Patient Care
-- Independent RESPECT-EPA Study Now Third in a Series of Trials to Underscore CV Risk Reduction Benefits of Eicosapentaenoic Acid for Patients -- -- PROMINENT Study Failed to Show CV Risk Reduction Benefit of the Fibrate Class for Statin-Treated High-Risk Patients -- DUBLIN, I
Read more →AMRNAmarin Reports Third Quarter 2022 Financial Results and Provides Business Update -- U.S. Business Trends Stabilize and Progress on Operational Initiatives Result in Extended Cash Runway -- -- Commenced Launch of VAZKEPA
Amarin Reports Third Quarter 2022 Financial Results and Provides Business Update -- U.S. Business Trends Stabilize and Progress on Operational Initiatives Result in Extended Cash Runway -- -- Commenced Launch of VAZKEPA (icosapent ethyl) in England & Wales Mid-October As Planne
Read more →AMRNAmarin to Report Third Quarter 2022 Financial Results And Host Conference Call on October 27, 2022
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin’s senior management team to discuss the Company’s third quarter 2022 financial results on Thurs
Read more →AMRNAMARIN APPOINTS ADAM BERGER AND GERALDINE MURPHY TO BOARD OF DIRECTORS Lars Ekman and Patrick O Sullivan to Retire from Amarin Board at year-end New Independent Directors Bring Significant International Experience in Hea
AMARIN APPOINTS ADAM BERGER AND GERALDINE MURPHY TO BOARD OF DIRECTORS Lars Ekman and Patrick O Sullivan to Retire from Amarin Board at year-end New Independent Directors Bring Significant International Experience in Healthcare and Finance Seventy-five Percent New Independent
Read more →AMRNAmarin Board of Directors Issues Statement in Response to Sarissa
-- Highlights Active Board Refreshment Process -- -- Amarin Has Engaged Proactively and Frequently with Sarissa -- DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today issued the following statement in response to S
Read more →AMRNAmarin to Present at H.C. Wainwright’s 24th Annual Global Investment Conference
DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin’s president and chief executive officer, is scheduled to participate at the H.C. Wainwright 24th Annual Global Investment Confe
Read more →AMRNAmarin Provides Update on VAZKEPA (icosapent ethyl) Pricing Negotiations in Germany Frankfurt am Main
Amarin Provides Update on VAZKEPA (icosapent ethyl) Pricing Negotiations in Germany Frankfurt am Main, August 19, 2022 Amarin Deutschland GmbH today announced that after the conclusion of the fourth and final round of negotiations with the National Association of Statutory Hea
Read more →AMRNAmarin Reports Second Quarter 2022 Financial Results and Provides Business Update Company Received Final Positive Reimbursement Decision for VAZKEPA by UK's NICE in England & Wales Market Access Negotiations and Launch P
Amarin Reports Second Quarter 2022 Financial Results and Provides Business Update Company Received Final Positive Reimbursement Decision for VAZKEPA by UK's NICE in England & Wales Market Access Negotiations and Launch Preparations for VAZKEPA Underway Across Multiple European
Read more →AMRNAmarin to Report Second Quarter 2022 Financial Results and Host Conference Call on August 3, 2022
DUBLIN, Ireland and BRIDGEWATER, N.J., July 20, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin’s senior management team to discuss the Company’s second quarter 2022 financial results on Wedn
Read more →AMRNAmarin Receives Positive Recommendation from United Kingdom’s (UK) National Institute for Health and Care Excellence (NICE) for Reimbursement of VAZKEPA (icosapent ethyl)
UK’s NICE issued its draft Final Appraisal Document (FAD) recommending the use of VAZKEPA® (icosapent ethyl) in England and Wales to reduce the risk of cardiovascular (CV) events in adult statin-treated patients at high CV risk who have elevated triglycerides (≥150 mg/dL [≥ 1.7 m
Read more →AMRNAMARIN ANNOUNCES COMPREHENSIVE COST REDUCTION PLAN TO ADDRESS MARKET DYNAMICS IN U.S. BUSINESS Company Expects to Achieve Approximately $100 Million in Cost Savings Over the Next 12 Months* While Continuing to Invest in
AMARIN ANNOUNCES COMPREHENSIVE COST REDUCTION PLAN TO ADDRESS MARKET DYNAMICS IN U.S. BUSINESS Company Expects to Achieve Approximately $100 Million in Cost Savings Over the Next 12 Months* While Continuing to Invest in European Launches and Global Expansion Reduces U.S. Comme
Read more →AMRNAmarin Appoints Tom Reilly as New Chief Financial Officer
-- Experienced Executive Brings More Than Twenty Years of Global Financial Leadership to Amarin -- -- Michael W. Kalb to Depart Amarin to Pursue Other Interests -- DUBLIN, Ireland and BRIDGEWATER, N.J., June 06, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) toda
Read more →AMRNAmarin Announces Appointment of New Directors and Board Leadership Changes
Erin Enright and Alfonso “Chito” Zulueta Appointed to Board of Directors New Board Members Bring Skills and Experience Aligned with the Company’s Strategy Per Wold-Olsen Named Chairman of the Board David Stack and Joe Zakrzewski to Retire from the Board Actions Reflect Compan
Read more →AMRNBoard Changes Press Release AMARIN ANNOUNCES APPOINTMENT OF NEW DIRECTORS AND BOARD LEADERSHIP CHANGES Erin Enright and Alfonso Chito Zulueta Appointed to Board of Directors New Board Members Bring Skills and Experience
Board Changes Press Release ANNOUNCES APPOINTMENT OF NEW DIRECTORS AND BOARD LEADERSHIP CHANGES Erin Enright and Alfonso Chito Zulueta Appointed to New Board Members Bring Skills and Experience Aligned with the Company s Strategy Per Wold-Olsen Named Chairman of the Board Da
Read more →AMRN▼ -43.1%on this news· ran to -54% by day 3
Amarin Reports First Quarter 2022 Financial Results and Provides Business Update Initiated Next Phase of European Expansion Strategy with First National Reimbursement in Sweden Market Access Negotiations and Launch Prepa
Amarin Reports First Quarter 2022 Financial Results and Provides Business Update Initiated Next Phase of European Expansion Strategy with First National Reimbursement in Sweden Market Access Negotiations and Launch Preparations for VAZKEPA Underway Across Multiple European Mark
Read more →AMRNAmarin Partner HLS Therapeutics Completes Reimbursement Negotiations with Pan-Canadian Pharmaceutical Alliance (pCPA) for VASCEPA (icosapent ethyl)
DUBLIN, Ireland and BRIDGEWATER, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced today its partner HLS Therapeutics has completed negotiations with Canada’s pan-Canadian Pharmaceutical Alliance (pCPA) for the terms and conditions under whic
Read more →AMRNAmarin to Report First Quarter 2022 Financial Results and Host Conference Call On May 4, 2022
DUBLIN, Ireland and BRIDGEWATER, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin’s senior management team to discuss the Company's first quarter 2022 financial results on Wedn
Read more →AMRNAmarin Receives Reimbursement for VAZKEPA in Sweden
Marks First Health Technology Assessment (HTA) Reimbursement in Europe and Initiation of Next Phase of the Company’s Growth Strategy Company Provides Progress Update on European and International Expansion Plans DUBLIN, Ireland and BRIDGEWATER, N.J., March 28, 2022 (GLOBE NEWSW
Read more →AMRNAmarin Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update Go-to-Market Strategy in U.S. to Optimize Provider Engagement and Drive Demand for VASCEPA European Expansion Strategy On Tr
Amarin Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update Go-to-Market Strategy in U.S. to Optimize Provider Engagement and Drive Demand for VASCEPA European Expansion Strategy On Track with Reimbursement Negotiations and Launch Preparation
Read more →AMRNAmarin to Participate in Cowen 42nd Annual Health Care Conference
DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 25, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that Karim Mikhail, president and chief executive officer of Amarin, is scheduled to participate virtually in a fireside chat at the Cowen 42nd Annual He
Read more →AMRN▲ +5.3%on this news
Amarin to Report Fourth Quarter and Full Year 2021 Financial Results And Host Conference Call on March 1, 2022
DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin’s senior management team to discuss the Company's fourth quarter and full year 2021 financial r
Read more →AMRNAmarin Provides Preliminary 2021 Revenue and Outlook for 2022 DUBLIN, Ireland and BRIDGEWATER, N.J.
Amarin Provides Preliminary 2021 Revenue and Outlook for 2022 DUBLIN, Ireland and BRIDGEWATER, N.J., January 10, 2022 -- Amarin Corporation plc (NASDAQ:AMRN) today provided a business update, including preliminary unaudited full-year 2021 revenue results. Amarin plans to discuss
Read more →AMRNAmarin to Present at the 40th Annual J.P. Morgan Healthcare Conference
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that Karim Mikhail, president and chief executive officer of Amarin, is scheduled to present virtually at the 40th Annual J.P. Morgan Healthcare Conferen
Read more →AMRNAMARIN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Amarin Corporation PLC and Encourages Investors to Contact the Firm
NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Amarin Corporation PLC (“Amarin” or the “Company”) (NASDAQ: AMRN) in the United State
Read more →AMRNAmarin Reports Overview of Latest Clinical Research Evaluating VASCEPA /VAZKEPA (Icosapent Ethyl) and Eicosapentaenoic Acid (EPA) Presented at the American Heart Association Scientific Sessions 2021
DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today reported an overview of new data relating to VASCEPA®/VAZKEPA (icosapent ethyl) presented at the American Heart Association (AHA) Scientific Sessions 2021, which to
Read more →AMRNAmarin Reports Subgroup Data from REDUCE-IT Highlighting Benefits of VASCEPA /VAZKEPA (Icosapent Ethyl) in Patients with Prior Peripheral Artery Disease (PAD) Presented in Rapid Fire Oral Session Presentation at the American Heart Association Scientific Sessions 2021
DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that data adding to the growing body of knowledge on VASCEPA®/VAZKEPA (icosapent ethyl) in patients with prior peripheral artery disease (PAD) at risk for
Read more →AMRN▼ -12%on this news
Amarin Reports Third Quarter 2021 Financial Results and Provides Business Update Launched VAZKEPA in Germany with Multiple European Country Launches Expected in 2022 Introduced New Go-to-Market Strategy in U.S. to Enhanc
Amarin Reports Third Quarter 2021 Financial Results and Provides Business Update Launched VAZKEPA in Germany with Multiple European Country Launches Expected in 2022 Introduced New Go-to-Market Strategy in U.S. to Enhance Awareness and Drive Demand for VASCEPA Plans for Regula
Read more →AMRNAmarin to Report Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company will host a conference call with members of Amarin’s senior management team to discuss the Company's third quarter 2021 financial results
Read more →AMRNAMARIN OUTLINES NEW GO-TO-MARKET STRATEGY TO ACCELERATE VASCEPA (ICOSAPENT ETHYL) GROWTH IN U.S. Enables Amarin to Drive Additional Demand, Improve Patient Access & Education and Secure Proper Fulfillment and Reimburseme
GO-TO-MARKET STRATEGY TO ACCELERATE VASCEPA (ICOSAPENT ETHYL) GROWTH IN U.S. Enables Amarin to Drive Additional Demand, Improve Patient Access & Education and Secure Proper Fulfillment and Reimbursement DUBLIN, Ireland and BRIDGEWATER, N.J., Sep. 22, 2021 Amarin Corporation plc
Read more →AMRNAmarin Announces First European Launch of VAZKEPA (icosapent ethyl) in Germany
DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the first European launch of VAZKEPA (icosapent ethyl) in Germany. VAZKEPA received marketing authorization from the European Commission in March 2021 an
Read more →AMRNAmarin to Participate in September Investment Conferences
DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that members of the senior leadership team will participate in two upcoming virtual investment conferences in September 2021. H. C. Wainwright 23rd Annu
Read more →AMRNAmarin Reports Overview of Latest Clinical Research Evaluating VASCEPA /VAZKEPA (Icosapent Ethyl) and Eicosapentaenoic Acid (EPA) Presented at ESC Congress 2021, Organized by the European Society of Cardiology
VASCEPA/VAZKEPA found in prespecified and post hoc analyses to reduce first and total primary endpoints by 26% and 35%, respectively, in REDUCE-IT patients with prior Myocardial Infarction 2021 ESC Guidelines on Cardiovascular Disease Prevention now include VAZKEPA in their reco
Read more →AMRN▲ +7.2%on this news
Amarin Reports Data from REDUCE-IT Showing VASCEPA /VAZKEPA (Icosapent Ethyl) Significantly Reduces Ischemic Events in Patients with Prior Heart Attacks Presented in Late Breaking Science Session at ESC Congress 2021, Organized by the European Society of Cardiology
VASCEPA found in prespecified and post hoc analyses to reduce first and total primary endpoints by 26% and 35%, respectively, in patients with prior Myocardial Infarction DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN
Read more →AMRN▲ +9.5%on this news
Amarin Reports Second Quarter and Six Month 2021 Financial Results and Provides Business Update Commercial Launch of VAZKEPA in Europe on Track to Commence in September in Germany Filed Several Market Access Dossiers in
Amarin Reports Second Quarter and Six Month 2021 Financial Results and Provides Business Update Commercial Launch of VAZKEPA in Europe on Track to Commence in September in Germany Filed Several Market Access Dossiers in Europe with Proposed Pricing of approximately 200 per Mont
Read more →AMRNAmarin to Report Second Quarter and Six Month 2021 Financial Results and Host Conference Call on August 5, 2021
DUBLIN, Ireland and BRIDGEWATER, N.J., July 15, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin senior management to discuss the company's second quarter and six month 2021 financial results
Read more →AMRNAmarin to Present at Two Investor Conferences in June 2021
DUBLIN, Ireland and BRIDGEWATER, N.J., May 18, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that John F. Thero, Amarin's president and chief executive officer, and Karim Mikhail, Amarin’s senior vice president and head of commercial for Europe and
Read more →AMRNAmarin Highlights Multiple Scientific Findings for VASCEPA (Icosapent Ethyl) and Its Unique Active Ingredient at the American College of Cardiology’s 70th Annual Scientific Session
REDUCE-IT® patients experienced substantial cardiovascular (CV) risk reduction with icosapent ethyl regardless of the presence or degree of dyslipidemia, as defined by various high TG plus low HDL-C levels Patients randomized to VASCEPA in EVAPORATE trial, in analyses of percent
Read more →AMRNAmarin Announces Planned Retirement of Joseph T. Kennedy, EVP, General Counsel
DUBLIN, Ireland and BRIDGEWATER, N.J., April 29, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced that Joseph T. Kennedy has informed the board of directors of his decision to retire as executive vice president, general counsel and strategic initiati
Read more →AMRNAmarin Reports First Quarter 2021 Financial Results and Provides Business Update Commercial Launch of VAZKEPA in Europe on Track to Commence in Q3 2021 Following Recent Market Authorization with VASCEPA Growth in the Uni
Amarin Reports First Quarter 2021 Financial Results and Provides Business Update Commercial Launch of VAZKEPA in Europe on Track to Commence in Q3 2021 Following Recent Market Authorization with VASCEPA Growth in the United States Positioned to Increase as the Impact of COVID-19
Read more →AMRNAmarin Receives Great Britain Marketing Authorization for VAZKEPA from the Medicines and Healthcare Products Regulatory Agency (MHRA) 1,2
VAZKEPA (icosapent ethyl) is the first and only authorized treatment for its cardiovascular risk reduction indication1,2,3 VAZKEPA authorization for Great Britain follows recent VAZKEPA authorization for European Union DUBLIN, Ireland and BRIDGEWATER, N.J., April 22, 2021 (GLOB
Read more →AMRNAmarin to Report First Quarter Results and Host Conference Call on April 29, 2021
DUBLIN, Ireland and BRIDGEWATER, N.J., April 20, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin senior management to discuss the company's first quarter 2021 financial results and provide an
Read more →AMRNAmarin Announces CEO Succession Plan
John Thero to Retire as President and CEO on August 1, 2021 Board Appoints Karim Mikhail, Current SVP and Head of Commercial for Europe, as Successor DUBLIN, Ireland and BRIDGEWATER, N.J., April 12, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced t
Read more →AMRNAmarin Announces CEO Succession Plan John Thero to Retire as President and CEO on
Amarin Announces CEO Succession Plan John Thero to Retire as President and CEO on August 1, 2021 Board Appoints Karim Mikhail, Current SVP and Head of Commercial for Europe, as Successor DUBLIN, Ireland and BRIDGEWATER, N.J., April 12, 2021 Amarin Corporation plc (NASDAQ:AMRN)
Read more →AMRNAmarin Commences Commercial Initiatives for VAZKEPA in European Union Following Recent Regulatory Approval for Cardiovascular Risk Reduction Indication
Reimbursement dossiers for first 10 countries to be filed in coming months 150 people hired and on-track to be deployed by mid-Q2 2021 supplemented by digital outreach and medical education programs with initial top priority on Germany VAZKEPA commercial launch in Germany plann
Read more →AMRNAmarin Receives European Commission (EC) Approval for VAZKEPA to Reduce Cardiovascular Risk
Marks first and only EC-approved treatment to reduce cardiovascular risk in high-risk, statin-treated adult patients who have elevated triglycerides (≥150 mg/dL) and other risk characteristics as studied in REDUCE-IT® 1, 2 DUBLIN, Ireland and BRIDGEWATER, N.J., March 30, 2021 (G
Read more →AMRNAmarin Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update Record Revenue of $614.1 Million and $167.3 Million for Full Year and Fourth Quarter 2020 Despite COVID-19 Impact Received P
Amarin Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update Record Revenue of $614.1 Million and $167.3 Million for Full Year and Fourth Quarter 2020 Despite COVID-19 Impact Received Positive CHMP Opinion for VAZKEPA in Europe and Continue t
Read more →AMRNAmarin to Report Fourth Quarter and Full Year 2020 Results and Host Conference Call on February 25, 2021
DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin senior management to discuss the company's fourth quarter and full year 2020 financial results
Read more →AMRNAmarin Provides Update on VASCEPA (Icosapent Ethyl) Regulatory Review Processes in Mainland China and Hong Kong
DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that its corporate partner in China, Edding, has progressed VASCEPA® (icosapent ethyl) into commencement of the regulatory review processes in Mainland Ch
Read more →AMRNAmarin Receives Positive CHMP Opinion for Icosapent Ethyl for Cardiovascular Risk Reduction
Positive opinion is based on extensive clinical study results, including results of the REDUCE-IT® cardiovascular outcomes study European Commission decision on the Marketing Authorisation Application expected in April 2021 DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 29, 2021 (
Read more →AMRNAmarin Expands Cardiovascular Risk Reduction Patent Infringement Lawsuit to Include Health Care Insurance Provider
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), announced today an expansion of the scope of its VASCEPA® (icosapent ethyl) cardiovascular (CV) risk reduction patent infringement lawsuit against Hikma Pharmaceuticals
Read more →AMRNAmarin Provides Preliminary 2020 Results and 2021 Outlook Unaudited 2020 Total Net Revenue Estimated to Be Approximately $610 Million, an Increase of Approximately 42% Compared with 2019 Completion of European Regulatory
Amarin Provides Preliminary 2020 Results and 2021 Outlook Unaudited 2020 Total Net Revenue Estimated to Be Approximately $610 Million, an Increase of Approximately 42% Compared with 2019 Completion of European Regulatory Review and Submission of China Regulatory Application fo
Read more →AMRNAmarin to Present at 39th Annual J.P. Morgan Healthcare Conference
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced today that John F. Thero, Amarin's president and chief executive officer, is scheduled to present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesda
Read more →AMRNAmarin Highlights Multiple VASCEPA (Icosapent Ethyl)-Related Scientific Findings Presented at National Lipid Association (NLA) Scientific Sessions 2020, Including First COVID-19 Clinical Results
REDUCE-IT® EPA Encore Presentation reinforces Eicosapentaenoic Acid (EPA) levels from VASCEPA® (icosapent ethyl) strongly correlated to cardiovascular outcomes, more so than other biomarkers VASCEPA COVID-19 CardioLink-9 Randomized Trial suggests improvement in outpatient-report
Read more →AMRNAmarin Reports Encouraging Efficacy and Safety Results from Pilot Study Treating COVID-19 Infected Outpatients with VASCEPA (Icosapent Ethyl) in Late Breaker Presentation at National Lipid Association (NLA) Scientific Sessions 2020
VASCEPA COVID-19 CardioLink-9 Randomized Trial suggests improvement in patient-reported COVID-19 symptoms while achieving its primary endpoint by demonstrating a 25% reduction in high-sensitivity C-reactive protein (hsCRP) with encouraging short-term safety and tolerability data
Read more →AMRNAmarin Files Patent Infringement Lawsuit Against Hikma
DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), announced today the filing of a patent infringement lawsuit by Amarin affiliates and a licensor against Hikma Pharmaceuticals PLC and Hikma’s U.S. affiliate. The lawsuit
Read more →AMRNAmarin to Present at Piper Sandler’s 32nd Annual Healthcare Conference (Virtual)
DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that John F. Thero, Amarin's president and chief executive officer, is scheduled to participate in a Fireside Chat at the Piper Sandler’s 32nd Annual Heal
Read more →AMRNAmarin Shares Topline Data from Partner’s Pivotal Phase 3 Study of VASCEPA (Icosapent Ethyl) in Mainland China
Significant Reduction in Triglyceride Levels Without Low-Density Lipoprotein Cholesterol (LDL-C) Increase Compared to Placebo and Safety Profile Similar to Placebo Achieved with 4 Grams Per Day Dose of Icosapent Ethyl in Chinese Patients with Very High Triglycerides (>500 mg/dL)
Read more →AMRNAmarin to Present at the Stifel 2020 Virtual Healthcare and Jefferies Virtual London Healthcare Conferences
DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that John F. Thero, Amarin's president and chief executive officer, is scheduled to present general company updates at the following investor conferences
Read more →AMRNAmarin Reports Third Quarter 2020 Financial Results and Provides Business Update Total Revenue Increased 39% in Third Quarter 2020 and 56% in First Nine Months of 2020 Compared to Same Periods of 2019 Despite COVID-19 He
Amarin Reports Third Quarter 2020 Financial Results and Provides Business Update Total Revenue Increased 39% in Third Quarter 2020 and 56% in First Nine Months of 2020 Compared to Same Periods of 2019 Despite COVID-19 Headwinds Progress Continues Towards VASCEPA (icosapent ethy
Read more →AMRNAmarin to Report Third Quarter 2020 Results and Host Conference Call on November 5, 2020
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin senior management to discuss the company's third quarter 2020 financial results and provide an
Read more →AMRNAmarin to Present at the 2020 Cantor Virtual Global Healthcare Conference
DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced today that John F. Thero, Amarin's president and chief executive officer, is scheduled to present at the 2020 Cantor Virtual Global Healthcare Conference on We
Read more →AMRNAmarin Provides Update Following Ruling in VASCEPA ANDA Patent Litigation DUBLIN, Ireland and BRIDGEWATER, N.J.
Amarin Provides Update Following Ruling in VASCEPA ANDA Patent Litigation DUBLIN, Ireland and BRIDGEWATER, N.J., September 3, 2020 Amarin Corporation plc (NASDAQ:AMRN) today provided an update following the decision by the U.S. Court of Appeals for the Federal Circuit in the c
Read more →AMRNAmarin Supports Latest Clinical Research Evaluating VASCEPA (Icosapent Ethyl) in Patients with Persistent Cardiovascular Risk Presented at ESC Congress 2020, the Annual Meeting of the European Society of Cardiology
VASCEPA is the first and only agent studied on top of statin therapy reported to exhibit coronary plaque regression in hypertriglyceridemic patients VASCEPA in REDUCE-IT® cardiovascular outcomes study achieved statistical significance for primary and secondary endpoints at prede
Read more →AMRNAmarin Supports Investigator-Initiated Trial at Kaiser Permanente in the U.S. to Study the Effects of VASCEPA (icosapent ethyl) in Reducing Viral Upper Respiratory Infections, Including COVID-19 and Flu, and the Clinical Severity of Such Infections
DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced support for an investigator-initiated trial to study the effects of icosapent ethyl (VASCEPA®) (IPE) on laboratory-confirmed viral upper respiratory infe
Read more →AMRNAmarin Reports Second Quarter 2020 Financial Results and Provides Update on Operations Total Revenue Increased 34% in Second Quarter 2020 Compared to Second Quarter 2019 Despite COVID-19 Headwinds Multiple Upcoming Miles
Amarin Reports Second Quarter 2020 Financial Results and Provides Update on Operations Total Revenue Increased 34% in Second Quarter 2020 Compared to Second Quarter 2019 Despite COVID-19 Headwinds Multiple Upcoming Milestones Regarding VASCEPA Opportunity in United States and
Read more →AMRNAmarin Announces Plans to Maximize Blockbuster Potential of VASCEPA (icosapent ethyl) in Europe
Amarin to Build Dedicated Organization to Retain Substantial Value of One of the Most Anticipated Cardiovascular Drug Products in Decades Veteran Cardiovascular Commercial Executive Hired to Lead Focused Launch DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 04, 2020 (GLOBE NEWSWIR
Read more →AMRNAmarin to Report Second Quarter 2020 Results and Host Conference Call on August 4, 2020
DUBLIN, Ireland and BRIDGEWATER, N.J., July 21, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin senior management to discuss the company's second quarter 2020 financial results and provide an
Read more →AMRNAmarin Announces Patent Litigation Settlement Agreement with Apotex Inc.
DUBLIN, Ireland and BRIDGEWATER, N.J., June 16, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced today a settlement agreement with Apotex Inc. (Apotex) that resolves patent litigation that would have resulted from the previously disclosed abbreviated new dr
Read more →AMRNAmarin Plans to Increase VASCEPA (icosapent ethyl) Promotion and Education
DUBLIN, Ireland and BRIDGEWATER, N.J., June 01, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced that it intends to increase the level and breadth of its promotion and education initiatives regarding VASCEPA® (icosapent ethyl). As early signs emerge
Read more →AMRNAmarin Supports Trial to Investigate the Effects of VASCEPA (icosapent ethyl) in the Treatment of COVID-19
DUBLIN, Ireland and BRIDGEWATER, N.J., May 21, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced support for a clinical trial to investigate the effects of icosapent ethyl (IPE) (VASCEPA®) on inflammatory biomarkers and other patient outcomes in indiv
Read more →AMRNAmarin Reports First Quarter 2020 Financial Results and Provides Update on Operations Total Revenue Increased 112% to $155 Million in First Quarter 2020 Compared to Prior Year Management to Host Conference Call at 7:30 a
Amarin Reports First Quarter 2020 Financial Results and Provides Update on Operations Total Revenue Increased 112% to $155 Million in First Quarter 2020 Compared to Prior Year Management to Host Conference Call at 7:30 a.m. ET Today DUBLIN, Ireland and BRIDGEWATER, N.J., April
Read more →AMRNAmarin to Report First Quarter 2020 Results and Host Conference Call on April 30, 2020
DUBLIN, Ireland and BRIDGEWATER, N.J., April 28, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin senior management to discuss the company's first quarter 2020 financial results and provide an
Read more →AMRNAmarin to Host Conference Call on April 13, 2020 to Provide Preliminary First Quarter 2020 Results and Operational Update
DUBLIN, Ireland and BRIDGEWATER, N.J., April 08, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with management on Monday, April 13, 2020, at 4:30 p.m. ET to discuss the company's preliminary first quarter 2020 fi
Read more →AMRNAmarin Highlights VASCEPA (Icosapent Ethyl)-Related Data Presented at American College of Cardiology’s Annual Scientific Session Together With World Congress of Cardiology (ACC.20/WCC)
DUBLIN, Ireland and BRIDGEWATER, N.J., March 31, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), hosted a webcast yesterday to discuss important data with study authors who presented at the American College of Cardiology’s 69th Annual Scientific Session Together Wi
Read more →AMRNAmarin Comments on Ruling in VASCEPA ANDA Litigation
Amarin Comments on Ruling in VASCEPA ANDA Litigation DUBLIN, Ireland and BRIDGEWATER, N.J., March 30, 2020 (GLOBE NEWSWIRE) Amarin Corporation plc (NASDAQ:AMRN) today commented on the United States District Court for the District of Nevada s ruling in favor of the generic compa
Read more →AMRNAmarin Takes Proactive Steps to Support Public Health Priorities
DUBLIN, Ireland and BRIDGEWATER, N.J., March 15, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a leader in preventative cardiovascular risk reduction therapy, today announced actions in support of public health initiatives to combat the COVID-19 pandemic. The CO
Read more →AMRNAmarin Reports Record Fourth Quarter and Full Year 2019 Financial Results and Provides Update on Operations Record Revenue of $429.8 Million and $143.3 Million for Full Year and Fourth Quarter 2019 Launch Commenced of VA
Amarin Reports Record Fourth Quarter and Full Year 2019 Financial Results and Provides Update on Operations Record Revenue of $429.8 Million and $143.3 Million for Full Year and Fourth Quarter 2019 Launch Commenced of VASCEPA as First and Only Drug with Its New Cardiovascular
Read more →AMRNAmarin To Report Fourth Quarter and Full Year 2019 Results and Host Conference Call on February 25, 2020
DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin senior management to discuss the company's fourth quarter and full year 2019 financial results
Read more →AMRNAmarin Honored by BioNJ with Innovator Award for VASCEPA Development and Regulatory Approval
DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), announced today that BioNJ awarded Amarin with an Innovator Award in recognition of the approval of a new indication for VASCEPA® (icosapent ethyl) by the U.S. Food and
Read more →AMRNAmarin Launches True To Your Heart, a Campaign to Educate People on Persistent Cardiovascular Risk
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the launch of True To Your Heart, an educational campaign to help people learn more about cardiovascular disease and how to better protect against persist
Read more →AMRNAmarin Provides Update to Preliminary 2019 Results and Further Details on 2020 Outlook Unaudited Full-Year 2019 Net Total Revenue Estimated At or Slightly Above Upper-End of Prior Guidance of $410 to $425 Million U.S. Sa
Amarin Provides Update to Preliminary 2019 Results and Further Details on 2020 Outlook Unaudited Full-Year 2019 Net Total Revenue Estimated At or Slightly Above Upper-End of Prior Guidance of $410 to $425 Million U.S. Sales Force Expansion On-Track for Doubling to 800 Sales P
Read more →AMRNAmarin to Present at 38th Annual J.P. Morgan Healthcare Conference
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced today that John F. Thero, Amarin's president and chief executive officer, is scheduled to present at the 38th Annual J.P. Morgan Healthcare Conference in San Fr
Read more →AMRNAmarin Receives FDA Approval of VASCEPA (icosapent ethyl) to Reduce Cardiovascular Risk
VASCEPA becomes the first and only FDA-approved medication for reducing cardiovascular risk beyond cholesterol lowering therapy in high-risk patients approved for treatment Millions of people in the United States qualify as treatment candidates for VASCEPA Cardiovascular diseas
Read more →AMRNAmarin Highlights Key REDUCE-IT -Related Data Presented at American Heart Association 2019 Scientific Sessions
REDUCE-IT USA results, in prespecified subgroup analyses, showed cardiovascular risk reductions across all endpoints, including 30% relative risk reduction in all-cause mortality New analysis determined icosapent ethyl (Vascepa®) is highly cost-effective in patients from the RE
Read more →AMRNAmarin’s John Thero Awarded EY Entrepreneur of The Year 2019 Life Sciences National Award
DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, announced today that John F. Thero, president and chief executive officer of Amarin, has been named
Read more →AMRNAmarin Announced FDA Advisory Committee Voted Unanimously (16-0) to Recommend Approval of Vascepa (icosapent ethyl) Capsules Label Expansion to Reduce Cardiovascular Risk Based on Landmark REDUCE-IT Outcomes Trial
Cardiovascular disease events like heart attacks, stroke and death affect millions of patients in the United States and are estimated to cost $500 billion annually Millions of high-risk patients with cardiovascular disease could benefit from this cost-effective therapy if expand
Read more →AMRNAmarin Corporation plc (NASDAQ:AMRN) Stock Trading Halted Today for Scheduled FDA Advisory Committee Review of sNDA Seeking New Indication for Vascepa (Icosapent Ethyl) to Reduce the Risk of Major Adverse Cardiovascular Events Based on Landmark REDUCE-IT Cardiovascular Outcomes Study
DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced that NASDAQ has halted trading of the company's shares. The U.S. Food and Drug Admin
Read more →AMRNAmarin to Present at the Jefferies 2019 London Healthcare Conference
DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health announced today that John F. Thero, Amarin's president and chief executive officer, is scheduled to p
Read more →AMRNAmarin Reports Third Quarter 2019 Financial Results and Provides Update on Operations Record Revenue Levels and Preparations On-Track for Further Expansion Management to Host Conference Call at 7:30 a.m. ET Today DUBLIN,
Amarin Reports Third Quarter 2019 Financial Results and Provides Update on Operations Record Revenue Levels and Preparations On-Track for Further Expansion Management to Host Conference Call at 7:30 a.m. ET Today DUBLIN, Ireland and BRIDGEWATER, N.J., November 5, 2019 -- Amari
Read more →AMRNAmarin to Report Third Quarter 2019 Results and Host Conference Call on November 5, 2019
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to disc
Read more →AMRNAmarin to Participate in the Cantor Global Healthcare Conference
DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's
Read more →AMRNAmarin to Participate in the H.C. Wainwright 21st Annual Global Investment Conference
BEDMINSTER, N.J. and DUBLIN, Ireland, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's p
Read more →AMRNAmarin Provides Overview on Growing Global Attention on REDUCE-IT™ Results and Cardiovascular Risk Management Beyond Cholesterol Management
Multiple Papers and Presentations Highlight REDUCE-IT and Vascepa® Potential Mechanisms of Action of Vascepa Becoming Better Understood American Heart Association References REDUCE-IT in Scientific Advisory BEDMINSTER, N.J. and DUBLIN, Ireland, Aug. 27, 2019 (GLOBE NEWSWIRE) -
Read more →AMRNAmarin to Participate in a Fireside Chat at Citi’s 14th Annual Biotech Conference
BEDMINSTER, N.J. and DUBLIN, Ireland, Aug. 21, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's p
Read more →AMRNAmarin Announces FDA Notification of Advisory Committee Meeting Planned to be Held in November 2019 in Connection With Vascepa REDUCE-IT sNDA
Amarin Announces FDA Notification of Advisory Committee Meeting Planned to be Held in November 2019 in Connection With Vascepa REDUCE-IT sNDA PDUFA Date Extension to End of December 2019 Expected Management to Host Conference Call Today at 7:00 p.m. ET BEDMINSTER, N.J. and D
Read more →AMRNAmarin Reports Second Quarter 2019 Financial Results and Operational Update Record Total Revenue of $100.8 Million Achieved in Q2 2019 Commercial Expansion Plans on Track in Anticipation of
Amarin Reports Second Quarter 2019 Financial Results and Operational Update Record Total Revenue of $100.8 Million Achieved in Q2 2019 Commercial Expansion Plans on Track in Anticipation of September 28, 2019 PDUFA Date for Vascepa If Approved, Vascepa to Become First Prescrip
Read more →AMRNAmarin Announces Underwriters’ Full Exercise of Option to Purchase Additional American Depositary Shares
BEDMINSTER, N.J., and DUBLIN, Ireland, July 29, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that, in connection with its previously announced underwritten public offering of American Depositary Shares (“ADSs”), the underwriters of the offering ha
Read more →AMRNAmarin to Report Second Quarter 2019 Results and Host Conference Call on July 31, 2019
BEDMINSTER, N.J., and DUBLIN, Ireland, July 24, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to disc
Read more →AMRNAmarin Prices Public Offering of American Depositary Shares
BEDMINSTER, N.J. and DUBLIN, Ireland, July 18, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced the pricing of the underwritten public offering of 22,222,223 American Depositary Shares ("ADSs") at a price to the public of $18.00 per ADS. The gross pr
Read more →AMRNAmarin Announces $400,000,000 Public Offering of American Depositary Shares BEDMINSTER, N.J., and
Amarin Announces $400,000,000 Public Offering of American Depositary Shares BEDMINSTER, N.J., and DUBLIN, Ireland, July 17, 2019 Amarin Corporation plc (NASDAQ: AMRN) today announced that it has commenced an underwritten public offering of $400,000,000 of its American Depositar
Read more →AMRNAMARIN PROVIDES MID-2019 UPDATE, INCLUDING COMMERCIALIZATION PLANS FOR VASCEPA AND UPDATES FULL YEAR 2019 REVENUE GUIDANCE Record Revenue Achieved in 1H19 Primarily Due to Increased Demand for Vascepa Guidance for Total
AMARIN PROVIDES MID-2019 UPDATE, INCLUDING COMMERCIALIZATION PLANS FOR VASCEPA AND UPDATES FULL YEAR 2019 REVENUE GUIDANCE BEDMINSTER, N.J. and DUBLIN, Ireland, July 2, 2019 Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular heal
Read more →AMRNAmarin’s John Thero Awarded NJ EY Entrepreneur of The Year 2019 Award for Life Sciences
BEDMINSTER, N.J. and DUBLIN, Ireland, June 21, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, president
Read more →AMRNAmarin to Present at the 2019 BMO Prescription For Success Healthcare Conference
BEDMINSTER, N.J. and DUBLIN, Ireland, June 18, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's p
Read more →AMRNAmarin to Present at the Goldman Sachs 40th Annual Global Healthcare Conference
BEDMINSTER, N.J. and DUBLIN, Ireland, June 04, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's p
Read more →AMRNAmarin to Present at the Jefferies 2019 Healthcare Conference
BEDMINSTER, N.J., and DUBLIN, Ireland, May 30, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's p
Read more →AMRNU.S. FDA GRANTS PRIORITY REVIEW FOR VASCEPA (ICOSAPENT ETHYL) SUPPLEMENTAL NEW DRUG APPLICATION SEEKING CARDIOVASCULAR RISK REDUCTION INDICATION - PDUFA date assigned is
U.S. FDA GRANTS PRIORITY REVIEW FOR VASCEPA (ICOSAPENT ETHYL) SUPPLEMENTAL NEW DRUG APPLICATION SEEKING CARDIOVASCULAR RISK REDUCTION INDICATION BEDMINSTER, N.J. and DUBLIN, Ireland, May 29, 2019 Amarin Corporation plc (NASDAQ:AMRN) announced today that its supplemental new dru
Read more →AMRNAmarin Reports First Quarter 2019 Financial Results and Provides Update on Operations Total Revenue Increased 67% to $73.3 Million in First Quarter 2019 Compared to Prior Year Management to Host Conference Call at 7:30 a
Amarin Reports First Quarter 2019 Financial Results and Provides Update on Operations Total Revenue Increased 67% to $73.3 Million in First Quarter 2019 Compared to Prior Year Management to Host Conference Call at 7:30 a.m. ET Today BEDMINSTER, N.J., and DUBLIN, Ireland, May 1
Read more →AMRNAmarin To Report First Quarter 2019 Results and Host Conference Call On May 1, 2019
BEDMINSTER, N.J. and DUBLIN, Ireland, April 24, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to disc
Read more →AMRNAmarin Submits Supplemental New Drug Application (sNDA) to U.S. FDA Seeking New Indication for Vascepa (icosapent ethyl) to Reduce the Risk of Major Adverse Cardiovascular Events Based on Landmark REDUCE-IT Cardiovascula
Amarin Submits Supplemental New Drug Application (sNDA) to U.S. FDA Seeking New Indication for Vascepa (icosapent ethyl) to Reduce the Risk of Major Adverse Cardiovascular Events Based on Landmark REDUCE-IT Cardiovascular Outcomes Study BEDMINSTER, N.J., and DUBLIN, Ireland, M
Read more →AMRNAMARIN CORPORATION PLC INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the District of New Jersey against Amarin Corporation plc
NEW YORK, March 07, 2019 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces the filing of a federal securities class action lawsuit in the United States District Court for the District of New Jersey on behalf of purchasers of the securities of Amarin Corpo
Read more →AMRNAmarin to Present at Cowen’s 39th Annual Health Care Conference
BEDMINSTER, N.J., and DUBLIN, Ireland, March 05, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's
Read more →AMRNAMARIN CORPORATION PLC INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the District of New Jersey against Amarin Corporation plc
NEW YORK, Feb. 27, 2019 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces the filing of a federal securities class action lawsuit in the United States District Court for the District of New Jersey on behalf of purchasers of the securities of Amarin Corpor
Read more →AMRNAmarin Reports Record Fourth Quarter and Full Year 2018 Financial Results and Provides Update on Operations Record Revenue of $229.2 Million and $77.3 Million for Full Year and Fourth Quarter 2018 REDUCE-IT sNDA Submissi
Amarin Reports Record Fourth Quarter and Full Year 2018 Financial Results and Provides Update on Operations Record Revenue of $229.2 Million and $77.3 Million for Full Year and Fourth Quarter 2018 REDUCE-IT sNDA Submission Remains on Schedule to be Filed Before the End of Q1 20
Read more →AMRNAmarin To Report Fourth Quarter and Full Year 2018 Results and Host Conference Call on February 27, 2019
BEDMINSTER, N.J. and DUBLIN, Ireland, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discu
Read more →AMRNAmarin to Present at the 8th Annual SVB Leerink Global Healthcare Conference
BEDMINSTER, N.J., and DUBLIN, Ireland, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's
Read more →AMRNAmarin Provides Preliminary 2018 Results and 2019 Outlook U.S. Sales Force Increased to 400 Sales Professionals for 2019 Following Unprecedented Positive Results of Vascepa Cardiovascular Outcomes Study Presented in Nove
Amarin Provides Preliminary 2018 Results and 2019 Outlook U.S. Sales Force Increased to 400 Sales Professionals for 2019 Following Unprecedented Positive Results of Vascepa Cardiovascular Outcomes Study Presented in November 2018 Unaudited Full-Year 2018 Net Total Revenue Esti
Read more →AMRNAmarin to Present at 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019
BEDMINSTER, N.J., and DUBLIN, Ireland, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's
Read more →AMRNAmarin to Participate in a Fireside Chat at Citi’s 2018 Global Healthcare Conference
BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 28, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's
Read more →AMRNAmarin Announces Proposed Public Offering of American Depositary Shares BEDMINSTER, N.J., and
Amarin Announces Proposed Public Offering of American Depositary Shares BEDMINSTER, N.J., and DUBLIN, Ireland, November 26, 2018 Amarin Corporation plc (NASDAQ: AMRN) today announced a registered underwritten public offering of its American Depositary Shares ( ADSs ). All of th
Read more →AMRNAmarin to Present at the Evercore ISI HealthCONx Conference
BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's
Read more →AMRNVascepa (icosapent ethyl) 26% Reduction in Key Secondary Composite Endpoint of Cardiovascular Death, Heart Attacks and Stroke Demonstrated in REDUCE-IT Supports 25% Overall Reduction in Five-Point Major Adverse Cardiovas
Vascepa (icosapent ethyl) 26% Reduction in Key Secondary Composite Endpoint of Cardiovascular Death, Heart Attacks and Stroke Demonstrated in REDUCE-IT Supports 25% Overall Reduction in Five-Point Major Adverse Cardiovascular Event Primary Composite E Cardiovascular Risk Reduct
Read more →AMRNAmarin to Present at the Jefferies 2018 London Healthcare Conference
BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's
Read more →AMRNAmarin Reports Third Quarter 2018 Financial Results and Provides Update on Operations Activities Underway to Support Planned Commercial Expansion Management to Host Conference Call at 7:30 a.m. ET Today BEDMINSTER, N.J.,
Amarin Reports Third Quarter 2018 Financial Results and Provides Update on Operations Activities Underway to Support Planned Commercial Expansion Management to Host Conference Call at 7:30 a.m. ET Today BEDMINSTER, N.J., and DUBLIN, Ireland, November 1, 2018 -- Amarin Corporat
Read more →AMRNAmarin Schedules Webcast Discussion of Primary REDUCE-IT™ Trial Results Following Presentation at 2018 Scientific Sessions of American Heart Association
Webcast to Commence at 7:15 p.m. CT / 8:15 p.m. ET, Saturday, November 10, 2018 BEDMINSTER, N.J. and DUBLIN, Ireland, Oct. 26, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics
Read more →AMRNAmarin To Report Third Quarter 2018 Results and Host Conference Call On November 1, 2018
BEDMINSTER, N.J. and DUBLIN, Ireland, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference
Read more →AMRNAmarin Announces Mandatory Exchange of Exchangeable Senior Notes Issued in January 2017 BEDMINSTER, N.J. and
Amarin Announces Mandatory Exchange of Exchangeable Senior Notes Issued in January 2017 BEDMINSTER, N.J. and DUBLIN, Ireland, October 19, 2018 Amarin Corporation plc (NASDAQ:AMRN) ( Amarin ), announced today that its wholly owned subsidiary, Corsicanto II Designated Activity Co
Read more →AMRNAmarin to Present at the Cantor Global Healthcare Conference
BEDMINSTER, N.J. and DUBLIN, Ireland, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's
Read more →AMRNREDUCE-IT Cardiovascular Outcomes Study of Vascepa (icosapent ethyl) Capsules Met Primary Endpoint REDUCE-IT Is First Outcomes Study to Assess Treatment of Patients with LDL-C Controlled by Statin Therapy, Persistent Ele
REDUCE-IT Cardiovascular Outcomes Study of Vascepa (icosapent ethyl) Capsules Met Primary Endpoint REDUCE-IT Is First Outcomes Study to Assess Treatment of Patients with LDL-C Controlled by Statin Therapy, Persistent Elevated Triglycerides and Other Cardiovascular Risk Factors
Read more →AMRNAmarin’s REDUCE-IT™ Clinical Study Now Positioned to be Next Large Cardiovascular Outcomes Study to Report Results
REDUCE-IT Study Remains On-Track for Report of Top-Line Results Before the End of September 2018 BEDMINSTER, N.J., and DUBLIN, Ireland, Aug. 26, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and develo
Read more →AMRNAmarin Reports Second Quarter 2018 Financial Results and Provides Update on Operations REDUCE-IT Study On-Track for Reporting Top-Line Results by the End of September 2018 Management to Host Conference Call at 7:30 a.m.
Amarin Reports Second Quarter 2018 Financial Results and Provides Update on Operations REDUCE-IT Study On-Track for Reporting Top-Line Results by the End of September 2018 Management to Host Conference Call at 7:30 a.m. ET Today BEDMINSTER, N.J., and DUBLIN, Ireland, August 1,
Read more →AMRNAmarin Announces Approval for Vascepa in United Arab Emirates
BEDMINSTER, N.J. and DUBLIN, Ireland, July 26, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, along with its commercial partner, Biologix
Read more →AMRNAmarin to Report Second Quarter 2018 Results and Host Conference Call on August 1, 2018
BEDMINSTER, N.J. and DUBLIN, Ireland, July 24, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a confere
Read more →AMRNAmarin Reports Last Patient Study Visit Has Occurred, an Important Step Towards Completion of REDUCE-IT™ Cardiovascular Outcomes Study
BEDMINSTER, N.J., and DUBLIN, Ireland, June 28, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that the last patient stud
Read more →AMRNAmarin and Mochida Announce Collaboration on Future Development of EPA-based Drug Products and Indications BEDMINSTER, N.J. and
Amarin and Mochida Announce Collaboration on Future Development of EPA-based Drug Products and Indications BEDMINSTER, N.J. and DUBLIN, Ireland, June 12, 2018 Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of
Read more →AMRNAmarin Sponsors Three Scientific Presentations Scheduled for American Diabetes Association Scientific Sessions
BEDMINSTER, N.J. and DUBLIN, Ireland, June 07, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, is supporting the presentation of three acc
Read more →AMRNAmarin Announces Patent Litigation Settlement Agreement with Teva
BEDMINSTER, N.J. and DUBLIN, Ireland, May 24, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today a settlement agreement with
Read more →AMRNAmarin to Present at the Jefferies Global Healthcare Conference
BEDMINSTER, N.J., and DUBLIN, Ireland, May 23, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin'
Read more →AMRNAmarin Reports First Quarter 2018 Financial Results and Provides Update on Operations REDUCE-IT Study On-Track for Reporting Top-Line Results by the End of Q3 2018 Management to Host Conference Call at 7:30 a.m. ET Today
Amarin Reports First Quarter 2018 Financial Results and Provides Update on Operations REDUCE-IT Study On-Track for Reporting Top-Line Results by the End of Q3 2018 Management to Host Conference Call at 7:30 a.m. ET Today BEDMINSTER, N.J., and DUBLIN, Ireland, May 2, 2018 -- Am
Read more →AMRNAmarin To Report First Quarter 2018 Results and Host Conference Call On May 2, 2018
BEDMINSTER, N.J. and DUBLIN, Ireland, April 26, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a confer
Read more →AMRNAmarin Announces Promotion of Aaron Berg to Position of Chief Commercial Officer BEDMINSTER, N.J., and
Amarin Announces Promotion of Aaron Berg to Position of Chief Commercial Officer BEDMINSTER, N.J., and DUBLIN, Ireland, April 23, 2018 Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve c
Read more →AMRNAmarin Sponsors Three Scientific Presentations Scheduled for National Lipid Association Scientific Sessions
BEDMINSTER, N.J. and DUBLIN, Ireland, April 12, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, is supporting the presentation of three a
Read more →AMRNAmarin’s REDUCE-IT Cardiovascular Outcomes Study Reaches 100% Mark for Estimated Onset of Target Primary Major Adverse Cardiovascular Events
BEDMINSTER, N.J., and DUBLIN, Ireland, April 04, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that its REDUCE-IT cardi
Read more →AMRNAmarin Updates First Quarter Revenue Guidance, Reiterates Full Year Guidance and Updates on REDUCE-IT Cardiovascular Outcomes Study Progress and Vascepa Promotion Initiatives Over 97% of Final Patient Visits in REDUCE-IT
Amarin Updates First Quarter Revenue Guidance, Reiterates Full Year Guidance and Updates on REDUCE-IT Cardiovascular Outcomes Study Progress and Vascepa Promotion Initiatives Over 97% of Final Patient Visits in REDUCE-IT Completed or Scheduled for Near-Term Completion BEDMINSTE
Read more →AMRNAmarin Sponsors Two Scientific Presentations Scheduled for National Kidney Foundation 2018 Spring Clinical Meetings
BEDMINSTER, N.J. and DUBLIN, Ireland, March 29, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, is supporting the presentation of two acc
Read more →AMRNAmarin to Present at the H.C. Wainwright Annual Global Life Sciences Conference
BEDMINSTER, N.J. and DUBLIN, Ireland, March 28, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin
Read more →AMRNAmarin Commemorates National Triglycerides Day on March 28
BEDMINSTER, N.J. and DUBLIN, Ireland, March 27, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, is proud to support and participate in the
Read more →AMRNAmarin Announces First Middle East Approval for Vascepa
BEDMINSTER, N.J. and DUBLIN, Ireland, March 21, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, along with Biologix FZCo, a company based
Read more →AMRNAmarin Announces Closing of Underwriter’s Purchase of Additional Shares
BEDMINSTER, N.J., and DUBLIN, Ireland, March 05, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that, in connection with its previously announced underwritten public offering of American Depositary Shares ("ADSs"), it has issued 1,438,356 additional
Read more →AMRNAmarin Announces Start of Final Clinical Site Visits in the REDUCE-IT Cardiovascular Outcomes Study
BEDMINSTER, N.J. and DUBLIN, Ireland, March 01, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that final study-related v
Read more →AMRNAmarin Sponsors Multiple Scientific Presentations Scheduled for 2018 American College of Cardiology Annual Scientific Session & Expo
BEDMINSTER, N.J. and DUBLIN, Ireland, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, is supporting the presentation of four acce
Read more →AMRNAmarin Reports Record Fourth Quarter and Full Year 2017 Financial Results and Provides Update on Operations Record Revenue of $181.1 Million and $53.9 Million for Full Year and Fourth Quarter 2017 REDUCE-IT Cardiovascula
Amarin Reports Record Fourth Quarter and Full Year 2017 Financial Results and Provides Update on Operations Record Revenue of $181.1 Million and $53.9 Million for Full Year and Fourth Quarter 2017 REDUCE-IT Cardiovascular Outcomes Study Remains on Schedule to Report Top-Line R
Read more →AMRNAmarin to Report Fourth Quarter and Full Year 2017 Results and Host Conference Call on February 27th, 2018
BEDMINSTER, N.J. and DUBLIN, Ireland, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a confere
Read more →AMRNAmarin’s REDUCE-IT Cardiovascular Outcomes Study Reaches 90% Mark for Reported Primary Events
BEDMINSTER, N.J. and DUBLIN, Ireland, Jan. 23, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that its REDUCE-IT cardiova
Read more →AMRNAmarin Announces Commencement of VASCEPA Clinical Development in Mainland China
BEDMINSTER, N.J. and DUBLIN, Ireland, Jan. 17, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics, today announced that a clinical trial of Vascepa® (icosapent ethyl) capsules
Read more →AMRNAmarin Provides Preliminary 2017 Results and Provides 2018 Outlook Unaudited Full-Year 2017 Net Product Revenue Estimated Between $177 and $180 Million, Exceeding Upper End of Previously Provided Guidance, with Fourth Qu
Amarin Provides Preliminary 2017 Results and Provides 2018 Outlook Unaudited Full-Year 2017 Net Product Revenue Estimated Between $177 and $180 Million, Exceeding Upper End of Previously Provided Guidance, with Fourth Quarter Estimate Between $51 and $54 Million Anticipate 20
Read more →AMRNAmarin Announces REDUCE-IT Cardiovascular Outcomes Study Final Patient Visits to Commence in March 2018
BEDMINSTER, N.J., and DUBLIN, Ireland, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced REDUCE-IT cardiovascular
Read more →AMRNAmarin to Present at 36th Annual J.P. Morgan Healthcare Conference in San Francisco
BEDMINSTER, N.J., and DUBLIN, Ireland, Dec. 18, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin
Read more →AMRNAmarin to Present at the Jefferies London Healthcare Conference
BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin
Read more →AMRNAmarin Reports Third Quarter 2017 Financial Results and Provides Update on Operations Record-High Net Product Revenue of $47.1 Million in Third Quarter Management to Host Conference Call Today at 8:00 a.m. ET BEDMINSTER,
Amarin Reports Third Quarter 2017 Financial Results and Provides Update on Operations Record-High Net Product Revenue of $47.1 Million in Third Quarter Management to Host Conference Call Today at 8:00 a.m. ET BEDMINSTER, N.J., and DUBLIN, Ireland, November 1, 2017 -- Amarin C
Read more →AMRNAmarin to Report Third Quarter 2017 Results and Host Conference Call on November 1, 2017
BEDMINSTER, N.J., and DUBLIN, Ireland, Oct. 25, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a confer
Read more →AMRNAmarin and HLS Therapeutics Announce Agreement to Commercialize Vascepa in Canada
BEDMINSTER, N.J., DUBLIN, Ireland, and TORONTO, Sept. 25, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) and HLS Therapeutics Inc. (“HLS”), announced today an exclusive agreement between the parties to register, commercialize and distribute Vascepa® (icosapent ethy
Read more →AMRNAmarin to Present at Cantor Global Healthcare Conference
BEDMINSTER, N.J., and DUBLIN, Ireland, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amari
Read more →AMRNAmarin Appoints Mark W. Salyer to New Position of Chief Commercial Officer
BEDMINSTER, N.J. and DUBLIN, Ireland, Sept. 13, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Mark W. Salyer has joined Amarin as Chief Commercial Officer. In this newly created position, Mr. Salyer will work to build on the company’s recent r
Read more →AMRNAmarin to Present at Rodman & Renshaw’s Global Investment Conference
BEDMINSTER, N.J., and DUBLIN, Ireland, Sept. 06, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amari
Read more →AMRNAmarin's REDUCE-IT Cardiovascular Outcomes Study of Vascepa to Continue as Planned at Recommendation of Independent Data Monitoring Committee
BEDMINSTER, N.J. and DUBLIN, Ireland, Aug. 14, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced that, as expected, the independent data monitoring committee (DMC) has completed its review of the scheduled pre-specified interim efficacy and safety analysis f
Read more →AMRNAmarin Reports Second Quarter 2017 Financial Results and Provides Update on Operations Record-High Net Product Revenue of $44.9 Million in Second Quarter Increasing Guidance on Full Year Net Product Revenue to $165-175 M
Amarin Reports Second Quarter 2017 Financial Results and Provides Update on Operations Record-High Net Product Revenue of $44.9 Million in Second Quarter Increasing Guidance on Full Year Net Product Revenue to $165-175 Million Management to Host Conference Call at 8:00 a.m. E
Read more →AMRNAmarin to Report Second Quarter 2017 Results and Host Conference Call on August 2, 2017
BEDMINSTER, N.J., and DUBLIN, Ireland, July 26, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a confer
Read more →AMRNAmarin Corporation plc (Nasdaq: AMRN) to Ring The Nasdaq Stock Market Opening Bell
ADVISORY, June 12, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, will visit the Nasdaq MarketSite in Times Square. In honor of the occ
Read more →AMRNAmarin to Present at the Jefferies 2017 Global Healthcare Conference
BEDMINSTER, N.J., and DUBLIN, Ireland, June 01, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin
Read more →AMRNAmarin Announces Expanded Research Relationships and Studies to Help Improve Cardiovascular Care
BEDMINSTER, N.J. and DUBLIN, Ireland, May 18, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today three new studies it is coor
Read more →AMRNAmarin Reports First Quarter 2017 Financial Results and Provides Update on Operations Prescription Growth Up 50%; Outcomes Study Beyond 80% Complete Re-affirms Guidance on Full Year Net Product Revenues of between $155 a
Amarin Reports First Quarter 2017 Financial Results and Provides Update on Operations Prescription Growth Up >50%; Outcomes Study Beyond 80% Complete Re-affirms Guidance on Full Year Net Product Revenues of between $155 and $165 Million Management to Host Conference Call at 8
Read more →AMRNAmarin to Report First Quarter 2017 Results and Host Conference Call on May 3, 2017
BEDMINSTER, N.J., and DUBLIN, Ireland, April 25, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a confe
Read more →AMRNAmarin Corporation CEO, John Thero, to Chair the American Heart Association’s Heart & Stroke Ball in New York City
NEW YORK, BEDMINSTER, N.J., and DUBLIN, Ireland, March 21, 2017 (GLOBE NEWSWIRE) -- The American Heart Association and American Stroke Association announced today that John Thero will serve as chairman of its annual Heart & Stroke Ball scheduled for June 14, 2017 in New York City
Read more →AMRNAmarin Reaches the Onset of Approximately 80% of the Target Aggregate Number of Primary Major Adverse Cardiovascular Events Within the REDUCE-IT Study
BEDMINSTER, N.J., and DUBLIN, Ireland, March 16, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today the onset of approximatel
Read more →AMRNAmarin Announces Publication of REDUCE-IT Cardiovascular Outcomes Study Rationale and Design in Clinical Cardiology
BEDMINSTER, N.J. and DUBLIN, Ireland, March 15, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced the publication today of the rationale and design for the company’s REDUCE-IT Phase 3 cardiovascular outcomes study in Clinical Cardiology, available at: http:/
Read more →AMRNAmarin Reports Record Fourth Quarter and Full Year 2016 Financial Results and Provides Update on Operations $130.1 Million and $38.7 Million Total Revenue for Full Year and Fourth Quarter 2016 Reflect Increases of 59% an
Amarin Reports Record Fourth Quarter and Full Year 2016 Financial Results and Provides Update on Operations $130.1 Million and $38.7 Million Total Revenue for Full Year and Fourth Quarter 2016 Reflect Increases of 59% and 45% Compared to Corresponding Periods in 2015 REDUCE-I
Read more →AMRNAmarin to Report Fourth Quarter and Full Year 2016 Results and Host Conference Call on February 28th, 2017
BEDMINSTER, N.J., and DUBLIN, Ireland, Feb. 22, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a confer
Read more →AMRNAmarin to Participate in the Leerink Partners 6th Annual Global Healthcare Conference
BEDMINSTER, N.J. and DUBLIN, Ireland, Feb. 09, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the company will parti
Read more →AMRNAmarin Announces Debt Restructuring and Related Private Placement of Exchangeable Senior Notes BEDMINSTER, N.J., and
Amarin Announces Debt Restructuring and Related Private Placement of Exchangeable Senior Notes BEDMINSTER, N.J., and DUBLIN, Ireland January 20, 2017 Amarin Corporation plc (Nasdaq: AMRN) ( Amarin ) announced today that it and its wholly owned subsidiary, Corsicanto II Designat
Read more →AMRNAmarin Provides Preliminary 2016 Results and 2017 Outlook Unaudited Full-Year 2016 Net Product Revenue Estimated to Modestly Exceed Upper End of $112 to $125 Million Previously Guided Range Anticipate Full-Year 2017 Net
Amarin Provides Preliminary 2016 Results and 2017 Outlook Unaudited Full-Year 2016 Net Product Revenue Estimated to Modestly Exceed Upper End of $112 to $125 Million Previously Guided Range Anticipate Full-Year 2017 Net Product Revenues Between $155 Million and $165 Million; Co
Read more →AMRNAmarin Announces Contractual Reminder of Optional Put to Holders of $15.1 million Principal Amount of Outstanding 3.50% Exchangeable Senior Notes Due 2032
BEDMINSTER, N.J. and DUBLIN, Ireland, Dec. 16, 2016 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) (the “Company”) announced today that it is providing a contractual reminder to holders of the outstanding 3.50% Exchangeable Senior Notes due 2032 (CUSIP Number: 220480 AC
Read more →AMRNAmarin Corporation plc One New Change London EC4M 9AF, England Dear Sirs, Re: Resignation from directorship of Amarin Corporation plc I write to confirm my resignation, effective as of 12:00 a.m. (Eastern time) on
Amarin Corporation plc London EC4M 9AF, England I write to confirm my resignation, effective as of 12:00 a.m. (Eastern time) on December 20, 2016, from the board of directors (including any committees thereof) of Amarin Corporation plc, a public limited company incorporated un
Read more →AMRNAmarin to Present at the Jefferies 2016 London Healthcare Conference
BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 11, 2016 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin
Read more →AMRNAmarin Reports Third Quarter 2016 Financial Results and Provides Update on Operations Third Quarter Net Product Revenue Up 52% vs. Prior Year Period Maintaining Guidance on 2016 Net Product Revenue at $112-$125 Million;
Amarin Reports Third Quarter 2016 Financial Results and Provides Update on Operations Third Quarter Net Product Revenue Up 52% vs. Prior Year Period Maintaining Guidance on 2016 Net Product Revenue at $112-$125 Million; Anticipate Upper Half of Range Management to Host Confe
Read more →AMRNAmarin to Report Third Quarter 2016 Results and Host Conference Call on November 3, 2016
BEDMINSTER, N.J. and DUBLIN, Ireland, Oct. 27, 2016 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a confere
Read more →AMRNAmarin s REDUCE-IT Cardiovascular Outcomes Study of Vascepa to Continue as Planned at Recommendation of Independent Data Monitoring Committee BEDMINSTER, NJ and DUBLIN, IRELAND
Amarin s REDUCE-IT Cardiovascular Outcomes Study of Vascepa to Continue as Planned at Recommendation of Independent Data Monitoring BEDMINSTER, NJ and DUBLIN, IRELAND September 12, 2016 Amarin Corporation plc (NASDAQ: AMRN) announced that, as expected, the independent data mon
Read more →AMRNAmarin to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
BEDMINSTER, N.J., and DUBLIN, Ireland, Sept. 07, 2016 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced that John F. Thero, Amarin's pr
Read more →AMRNAmarin Randomizes Final Patient into REDUCE-IT Cardiovascular Outcomes Study of Vascepa
BEDMINSTER, N.J. and DUBLIN, Ireland, Aug. 31, 2016 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced that randomization of patients into the REDUCE-IT cardiovascular outcomes study has been completed with 8,175 individual patients randomized, in accordance with
Read more →AMRNAmarin Announces Mandatory Exchange of Exchangeable Senior Notes Issued in May 2014 and November 2015 BEDMINSTER, N.J. and
Amarin Announces Mandatory Exchange of Exchangeable Senior Notes Issued in May 2014 and November 2015 BEDMINSTER, N.J. and DUBLIN, Ireland, August 26, 2016 Amarin Corporation plc (NASDAQ: AMRN) ( Amarin ), announced today that its wholly owned subsidiary, Corsicanto Limited, a
Read more →AMRNAmarin Announces Underwriters Exercise of Option to Purchase Additional American Depositary Shares BEDMINSTER, N.J., and
Amarin Announces Underwriters Exercise of Option to Purchase Additional American Depositary Shares BEDMINSTER, N.J., and DUBLIN, Ireland, August 15, 2016 Amarin Corporation plc (NASDAQ: AMRN) today announced that, in connection with its previously announced underwritten public
Read more →AMRNAmarin Reports Second Quarter 2016 Financial Results and Provides Update on Operations Second Quarter Net Product Revenue Up 85% vs. Prior Year Period Increasing Guidance on Full Year Net Product Revenue to $112-$125 Mil
Amarin Reports Second Quarter 2016 Financial Results and Provides Update on Operations Second Quarter Net Product Revenue Up 85% vs. Prior Year Period Increasing Guidance on Full Year Net Product Revenue to $112-$125 Million Management to Host Conference Call at 7:30 a.m. ET T
Read more →AMRNAmarin Appoints Michael W. Kalb Chief Financial Officer BEDMINSTER, N.J., and
Amarin Appoints Michael W. Kalb Chief Financial Officer BEDMINSTER, N.J., and DUBLIN, Ireland, June 30, 2016 Amarin Corporation plc (NASDAQ: AMRN) announced that starting today Michael W. Kalb has joined its senior management team as senior vice president and chief financial of
Read more →AMRNAmarin Reports First Quarter 2016 Financial Results and Provides Update on Operations Product revenue up 63% over prior year REDUCE-IT cardiovascular outcomes study achieves target enrollment Preparation for interim anal
Amarin Reports First Quarter 2016 Financial Results and Provides Update on Operations Product revenue up 63% over prior year REDUCE-IT cardiovascular outcomes study achieves target enrollment Preparation for interim analysis by independent data monitoring committee underway M
Read more →AMRNAmarin Reports Fourth Quarter and Year-End 2015 Financial Results and Provides Update on Operations 62% Increase in Fourth Quarter and 51% Increase in Full-Year Total Revenue Compared to 2014 REDUCE-IT Cardiovascular Out
Amarin Reports Fourth Quarter and Year-End 2015 Financial Results and Provides Update on Operations 62% Increase in Fourth Quarter and 51% Increase in Full-Year Total Revenue Compared to 2014 REDUCE-IT Cardiovascular Outcomes Study Continuing on Schedule Conference Call Set fo
Read more →AMRNAmarin Reports Preliminary 2015 Net Product Sales and Provides 2016 Revenue and Business Outlook 2015 Net Product Revenue Estimated to be Approximately $26.0 million for the Fourth Quarter and $80 Million for the Full Ye
Amarin Reports Preliminary 2015 Net Product Sales and Provides 2016 Revenue and Business Outlook 2015 Net Product Revenue Estimated to be Approximately $26.0 million for the Fourth Quarter and $80 Million for the Full Year, Exceeding Anticipate Full-Year 2016 Net Product Revenu
Read more →AMRNAmarin Reports Third Quarter 2015 Financial Results and Provides Update on Operations - REDUCE-IT cardiovascular outcomes study progressing as planned - - Net product revenue increased 51% over same period last year - -
Amarin Reports Third Quarter 2015 Financial Results and Provides Update on Operations - REDUCE-IT cardiovascular outcomes study progressing as planned - - Net product revenue increased 51% over same period last year - - Conference Call Set for 8:00 a.m. ET Today - BEDMINSTER
Read more →AMRNAmarin Reports Second Quarter 2015 Financial Results and Provides Update on Operations - REDUCE-IT cardiovascular outcomes study progressing as planned - - Product revenue increased 40% over same period last year - - Con
Amarin Reports Second Quarter 2015 Financial Results and Provides Update on Operations - REDUCE-IT cardiovascular outcomes study progressing as planned - - Product revenue increased 40% over same period last year - - Conference Call Set for 4:30 p.m. ET Today - BEDMINSTER, N
Read more →AMRNAmarin Reports First Quarter 2015 Financial Results and Provides Update on Operations -REDUCE-IT cardiovascular outcomes study continuing on schedule- -Product revenue increased 42% over same period last year- - Conferen
Amarin Reports First Quarter 2015 Financial Results and Provides Update on Operations -REDUCE-IT cardiovascular outcomes study continuing on schedule- -Product revenue increased 42% over same period last year- - Conference Call Set for 8:00 a.m. EST Today - BEDMINSTER, N.J.,
Read more →AMRNAmarin Announces $52.8 Million Private Placement
Amarin Announces $52.8 Million Private Placement BEDMINSTER, NJ and DUBLIN, IRELAND (Marketwired) 03/06/15 Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today
Read more →AMRNAmarin Reports Fourth Quarter and Year-End 2014 Financial Results and Provides Update on Operations -Revenues of $54.2 million for 2014 more than double 2013 revenues of $26.4 million- -REDUCE-IT cardiovascular outcomes
Amarin Reports Fourth Quarter and Year-End 2014 Financial Results and Provides Update on Operations -Revenues of $54.2 million for 2014 more than double 2013 revenues of $26.4 million- -REDUCE-IT cardiovascular outcomes study continuing on schedule- -Ex-US licensing further v
Read more →AMRNAmarin Reports Third Quarter 2014 Financial Results and Provides Update on Operations - Conference Call Set for 4:30 p.m. EST Today - BEDMINSTER, N.J., and
Amarin Reports Third Quarter 2014 Financial Results and Provides Update on Operations - Conference Call Set for 4:30 p.m. EST Today - BEDMINSTER, N.J., and DUBLIN, Ireland, November 6, 2014 Amarin Corporation plc (Nasdaq: AMRN), a biopharmaceutical company focused on the comm
Read more →AMRNAmarin Reports Second Quarter 2014 Financial Results and Provides Update on Operations - Conference Call Set for 4:30 p.m. EST Today - BEDMINSTER, N.J., and
Amarin Reports Second Quarter 2014 Financial Results and Provides Update on Operations - Conference Call Set for 4:30 p.m. EST Today - BEDMINSTER, N.J., and DUBLIN, Ireland, August 7, 2014 Amarin Corporation plc (Nasdaq: AMRN), a biopharmaceutical company focused on the comme
Read more →AMRNAmarin Announces Private Exchange Transactions Regarding Outstanding Senior Exchangeable Notes First put option date moved from 2017 to 2019 for exchanged notes BEDMINSTER, N.J., and
Amarin Announces Private Exchange Transactions Regarding Outstanding Senior Exchangeable Notes First put option date moved from 2017 to 2019 for exchanged notes BEDMINSTER, N.J., and DUBLIN, Ireland May 15, 2014 Amarin Corporation plc (Nasdaq: AMRN) ( Amarin ), announced today
Read more →AMRNAmarin Reports First Quarter 2014 Financial Results and Provides Update on Operations - Conference Call Set for 8:00 a.m. EST Today - BEDMINSTER, N.J., and
Amarin Reports First Quarter 2014 Financial Results and Provides Update on Operations - Conference Call Set for 8:00 a.m. EST Today - BEDMINSTER, N.J., and DUBLIN, Ireland, May 9, 2014 Amarin Corporation plc (Nasdaq: AMRN), a biopharmaceutical company focused on the commercia
Read more →AMRNAmarin to Report First Quarter 2014 Results and Host Conference Call on May 9, 2014
BEDMINSTER, N.J., and DUBLIN, Ireland, May 5, 2014 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conferen
Read more →AMRNAmarin Announces Presentation of New MARINE and ANCHOR Post-Hoc Analyses at National Lipid Association Annual Scientific Sessions Showing Vascepa(R) Significantly Reduced Apolipoprotein C-III Levels
BEDMINSTER, N.J., and DUBLIN, Ireland, May 2, 2014 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today the presentation at the Nati
Read more →AMRNAmarin and Kowa Pharmaceuticals America, Inc. Announce U.S. Co-Promotion Agreement for Vascepa (icosapent ethyl) Capsules Agreement to More than Double Vascepa Sales Calls and Expand Promotional Breadth and Depth BEDMINS
Amarin and Kowa Pharmaceuticals America, Inc. Announce U.S. Co-Promotion Agreement for Vascepa (icosapent ethyl) Capsules Agreement to More than Double Vascepa Sales Calls and Expand Promotional Breadth and Depth BEDMINSTER, N.J., DUBLIN, Ireland, and MONTGOMERY, AL, March 31
Read more →AMRNAmarin Reports Fourth Quarter and Year-End 2013 Financial Results and Provides Update on Operations - Conference Call Set for 4:30 p.m. EST Today - BEDMINSTER, N.J., and
Amarin Reports Fourth Quarter and Year-End 2013 Financial Results and Provides Update on Operations - Conference Call Set for 4:30 p.m. EST Today - BEDMINSTER, N.J., and DUBLIN, Ireland, February 27, 2014 Amarin Corporation plc (Nasdaq: AMRN), a late stage biopharmaceutical co
Read more →AMRNAmarin to Report Fourth Quarter and Year-End 2013 Results and Host Conference Call on February 27, 2014
BEDMINSTER, N.J. and DUBLIN, Ireland, Feb. 24, 2014 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a confere
Read more →AMRNAmarin Announces FDA Award of Three-Year Exclusivity for Vascepa(R) (icosapent ethyl) Capsules
BEDMINSTER, N.J. and DUBLIN, Ireland, Feb. 21, 2014 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the U.S. Food and Drug
Read more →AMRNAmarin to Present at the 2014 Leerink Global Healthcare Conference
BEDMINSTER, N.J., and DUBLIN, Ireland, Feb. 6, 2014 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced that John F. Thero, Amarin's Pres
Read more →AMRNAmarin Announces Promotion of Aaron Berg to Senior Vice President, Marketing and Sales
BEDMINSTER, N.J., and DUBLIN, Ireland, Feb. 4, 2014 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that industry veteran, Aaro
Read more →AMRNAmarin Announces FDA Review Division Response to ANCHOR SPA Agreement Reinstatement Request Conference Call Set for 8:00 a.m. ET today - Amarin Plans Appeal to FDA Office Level, No FDA sNDA Action Expected During Appeal
Amarin Announces FDA Review Division Response to ANCHOR SPA Agreement Reinstatement Request Conference Call Set for 8:00 a.m. ET today - Amarin Plans Appeal to FDA Office Level, No FDA sNDA Action Expected During Appeal - BEDMINSTER, N.J., and DUBLIN, Ireland, January 21, 201
Read more →AMRNAmarin Announces FDA Review Division Response on ANCHOR SPA Agreement Reinstatement Request Will Be Delayed
BEDMINSTER, N.J., and DUBLIN, Ireland, Jan. 15, 2014 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the Division of Metab
Read more →AMRNAmarin Receives FDA Notification That Action on ANCHOR sNDA Review Will be Delayed
BEDMINSTER, N.J. and DUBLIN, Ireland, Dec. 20, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the U.S. Food and Drug
Read more →AMRNAmarin Announces Leadership Changes
BEDMINSTER, N.J., and DUBLIN, Ireland, Dec. 16, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today the appointment of current
Read more →AMRNAmarin Announces Notification of Patent Allowances for U.S. Applications 13/685,281, and 13/685,291 Related to Triglyceride Lowering With a Mixture of Omega-3 Free Fatty Acid (Including EPA and/or DHA) in Both the MARINE and ANCHOR Patient Populations
BEDMINSTER, N.J., and DUBLIN, Ireland, Dec. 2, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the United States Pate
Read more →AMRNAmarin Reports Third Quarter 2013 Financial Results and Provides Update on Operations - Amarin pursuing reinstatement of Special Protocol Assessment agreement for ANCHOR study - BEDMINSTER, N.J., and
Amarin Reports Third Quarter 2013 Financial Results and Provides Update on Operations - Amarin pursuing reinstatement of Special Protocol Assessment agreement for ANCHOR study - BEDMINSTER, N.J., and DUBLIN, Ireland, November 7, 2013 Amarin Corporation plc (Nasdaq: AMRN), a la
Read more →AMRNAmarin to Report Third Quarter 2013 Results and Host Conference Call on November 7, 2013
BEDMINSTER, N.J., and DUBLIN, Ireland, Oct. 31, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a confer
Read more →AMRNAmarin Announces Plans to Reduce Expenses by Decreasing Staff Following Recent FDA Advisory Committee Vote
BEDMINSTER, N.J. and DUBLIN, Ireland, Oct. 22, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today plans to reduce operating e
Read more →AMRNAmarin Corporation (NASDAQ: AMRN) Stock Trading Halted Today; FDA Advisory Committee to Review sNDA for Vascepa(R) ANCHOR Indication
BEDMINSTER, N.J., and DUBLIN, Ireland, Oct. 16, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that NASDAQ has halted tra
Read more →AMRNAmarin Announces FDA Advisory Committee Outcome for the Use of Vascepa in the Treatment of High Triglycerides With Mixed Dyslipidemia
BEDMINSTER, N.J. and DUBLIN, Ireland, Oct. 16, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the U.S. Food and Drug
Read more →AMRNAmarin to Host Conference Call on October 16, 2013 to Discuss Results of FDA Advisory Committee Meeting on ANCHOR Supplemental New Drug Application (sNDA) for Vascepa(R)
Approval of the ANCHOR sNDA Would Expand Use of Vascepa to Include the Treatment of Patients with High Triglycerides ( 200 mg/dL and <500 mg/dL) with Mixed Dyslipidemia BEDMINSTER, N.J., and DUBLIN, Ireland, Oct. 9, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN),
Read more →AMRNAmarin Informed by FDA That October 16th Advisory Committee Meeting Will Take Place as Scheduled
BEDMINSTER, N.J. and DUBLIN, Ireland, Oct. 3, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that it was notified by the
Read more →AMRNAmarin Announces Enrollment of the REDUCE-IT Cardiovascular Outcomes Study Surpasses 6,000 Patients
BEDMINSTER, N.J., and DUBLIN, Ireland, Sept. 25, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the number of patien
Read more →AMRNAmarin to Present at the 2013 Aegis Capital Healthcare Conference
BEDMINSTER, N.J. and DUBLIN, Ireland, Sept. 18, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced that John F. Thero, Amarin's Pre
Read more →AMRNAmarin Announces 30th Patent for Vascepa(R)
BEDMINSTER, N.J., and DUBLIN, Sept. 9, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that it now has 30 patents issued o
Read more →AMRNAmarin Announces Submission of Supplemental New Drug Application for Novasep as Fourth Vascepa(R) Active Pharmaceutical Ingredient Supplier
BEDMINSTER, N.J. and DUBLIN, Ireland, Aug. 26, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today the submission of a Supplem
Read more →AMRNAmarin to Present at the Canaccord Genuity 33rd Annual Growth Conference
BEDMINSTER, N.J. and DUBLIN, Ireland, Aug. 13, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced that John F. Thero, Amarin's Pres
Read more →AMRNAmarin Reports Second Quarter 2013 Financial Results and Provides Update on Operations - Conference Call Set for 4:30 p.m. EST Today - BEDMINSTER, N.J., and
Amarin Reports Second Quarter 2013 Financial Results and Provides Update on Operations - Conference Call Set for 4:30 p.m. EST Today - BEDMINSTER, N.J., and DUBLIN, Ireland, August 8, 2013 Amarin Corporation plc (Nasdaq: AMRN), a late-stage biopharmaceutical company focused o
Read more →AMRNAmarin to Report Second Quarter 2013 Results and Host Conference Call on August 8, 2013
BEDMINSTER, N.J. and DUBLIN, Ireland, Aug. 2, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conferen
Read more →AMRNAmarin Announces Completion of Offering of American Depositary Shares
BEDMINSTER, N.J. and DUBLIN, Ireland, July 12, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN) ("Amarin" or the "Company") today announced that it had completed its previously announced underwritten public offering of 21,700,000 American Depositary Shares ("ADSs").
Read more →AMRNAmarin Announces Public Offering of American Depositary Shares BEDMINSTER, N.J., and DUBLIN
Amarin Announces Public Offering of American Depositary Shares BEDMINSTER, N.J., and DUBLIN, July 8, 2013 Amarin Corporation plc (Nasdaq: AMRN) ( Amarin or the Company ) today announced that it is offering to sell 21,700,000 American Depositary Shares ( ADSs ) in an underwritt
Read more →AMRNAmarin Announces Positive Results of Phase 1 Clinical Trial Measuring the Bioavailability of a Fixed-Dose Combination of Vascepa(R) and a Statin Compared to Concomitant Administration
BEDMINSTER, N.J., and DUBLIN, Ireland, June 21, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today the results from a Phase
Read more →AMRNAmarin Informed by FDA of October 16 th Advisory Committee Date in Connection with Supplemental New Drug Application (sNDA) for Vascepa (R) in the Treatment of Patients with High Triglycerides ( 200 mg/dL and 500 mg/dL)
Amarin Informed by FDA of October 16th Advisory Committee Date in Connection with Supplemental New Drug Application (sNDA) for Vascepa(R) in the Treatment of Patients with High Triglycerides (>200 mg/dL and <500 mg/dL) with Mixed Dyslipidemia -Submission for Indication Studied
Read more →AMRNAmarin Informed by FDA of October 16th Advisory Committee Date in Connection With Supplemental New Drug Application (sNDA) for Vascepa(R) in the Treatment of Patients With High Triglycerides (>200 mg/dL and <500 mg/dL) With Mixed Dyslipidemia
BEDMINSTER, N.J. and DUBLIN, Ireland, June 19, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that it was informed yester
Read more →AMRNAmarin Announces Additional Effects of Vascepa(R) on Lipoprotein Particle Concentration From the ANCHOR Study Presented at the National Lipid Association 2013 Annual Scientific Sessions
BEDMINSTER, N.J. and DUBLIN, Ireland, May 30, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today presented additional data on Vascepa (
Read more →AMRNAmarin to Present at the Jefferies 2013 Global Healthcare Conference
BEDMINSTER, N.J. and DUBLIN, Ireland, May 30, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced that John F. Thero, Amarin's Presi
Read more →AMRNAmarin Announces Notification of Patent Allowance for U.S. Application 13/417,899 Related to Combination Product of Vascepa(R) and Statin Therapy
BEDMINSTER, N.J., and DUBLIN, Ireland, May 22, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the United States Pate
Read more →AMRNAmarin Reports First Quarter 2013 Financial Results and Provides Update on Operations - Conference Call Set for 4:30 p.m. EST Today - BEDMINSTER, N.J., and
Amarin Reports First Quarter 2013 Financial Results and Provides Update on Operations - Conference Call Set for 4:30 p.m. EST Today - BEDMINSTER, N.J., and DUBLIN, Ireland, May 9, 2013 Amarin Corporation plc (Nasdaq: AMRN), a late-stage biopharmaceutical company focused on th
Read more →AMRNAmarin to Report First Quarter 2013 Results and Host Conference Call on May 9, 2013
BEDMINSTER, N.J. and DUBLIN, May 3, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call wi
Read more →AMRNAmarin Announces Approval of Supplemental New Drug Application for BASF as Additional Vascepa(R) Active Pharmaceutical Ingredient Supplier
BEDMINSTER, N.J. and DUBLIN, Ireland, April 30, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today the approval of the Supple
Read more →AMRNAmarin Announces FDA Acceptance of Supplemental New Drug Application (sNDA) for Vascepa(R) for the Treatment of Patients With High Triglycerides (>200 mg/dL and <500 mg/dL) With Mixed Dyslipidemia
BEDMINSTER, N.J. and DUBLIN, Ireland, April 23, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the Food and Drug Adm
Read more →AMRNAmarin Announces Approval of Supplemental New Drug Application for Chemport as Additional Vascepa(R) Active Pharmaceutical Ingredient Supplier
BEDMINSTER, N.J. and DUBLIN, Ireland, April 18, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today the approval of the Supple
Read more →AMRNAmarin Announces New Clinical Data Showing Significant Reductions in Apolipoprotein C-III Levels in MARINE and ANCHOR Studies of Vascepa(R)
BEDMINSTER, N.J., and DUBLIN, Ireland, April 8, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today additional data from Amari
Read more →AMRNAmarin Announces Notification of Patent Allowance for U.S. Application 13/614,111 Related to Vascepa(R) and Planned ANCHOR Indication
BEDMINSTER, N.J., and DUBLIN, Ireland, March 7, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the United States Pat
Read more →AMRNAmarin Reports Fourth Quarter and Year-End 2012 Financial Results and Provides Update on Operations - Conference Call Set for 4:30 p.m. EST Today - BEDMINSTER, N.J., and
Amarin Reports Fourth Quarter and Year-End 2012 Financial Results and Provides Update on Operations - Conference Call Set for 4:30 p.m. EST Today - BEDMINSTER, N.J., and DUBLIN, Ireland, Feb. 28, 2013 Amarin Corporation plc (Nasdaq: AMRN), a late-stage biopharmaceutical compa
Read more →AMRNAmarin Announces Submission of Supplemental New Drug Application (sNDA) for Vascepa(R) for the Treatment of Patients With High Triglycerides With Mixed Dyslipidemia
BEDMINSTER, N.J. and DUBLIN, Ireland, Feb. 26, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that it has submitted a Sup
Read more →AMRNAmarin to Report Fourth Quarter and Year-End 2012 Results and Host Conference Call on February 28, 2013
BEDMINSTER, N.J., and DUBLIN, Ireland, Feb. 22, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a confer
Read more →AMRNAmarin to Present at the CITI 2013 Global Healthcare Conference
BEDMINSTER, N.J., and DUBLIN, Ireland, Feb. 21, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced that Joseph Zakrzewski, Amarin's
Read more →AMRNAmarin Announces Notification of Patent Allowance for U.S. Application 13/614,129 Related to Vascepa(R) and FDA Approved MARINE Indication
BEDMINSTER, N.J. and DUBLIN, Ireland, Feb. 12, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the United States Pate
Read more →AMRNAmarin to Present at the Leerink Swann Global Healthcare Conference 2013
BEDMINSTER, N.J., and DUBLIN, Ireland, Feb. 7, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced that John F. Thero, Amarin's Pres
Read more →AMRNAmarin Announces Notification of Patent Allowance for U.S. Application 13/614,146 Related to Vascepa(R) and FDA Approved MARINE Indication
BEDMINSTER, N.J., and DUBLIN, Ireland, Feb. 7, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the United States Pate
Read more →AMRNAmarin Announces Notification of Additional U.S. Patent Allowance for U.S. Application 13/272,520 Based on ANCHOR Clinical Trial Results
Patent Application Related to High ( 200 mg/dL to <500 mg/dL) Triglyceride Patient Population With Mixed Dyslipidemia BEDMINSTER, N.J. and DUBLIN, Ireland, Feb. 1, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercia
Read more →AMRNAmarin Announces Notification of Two Additional Patent Allowances for U.S. Applications (13/458,496 and 13/349,157) Related to Vascepa(R) and FDA Approved MARINE Indication
BEDMINSTER, N.J. and DUBLIN, Ireland, Jan. 31, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the United States Pate
Read more →AMRNAmarin Announces Market Introduction of Vascepa(R) (icosapent ethyl) Capsules for the Treatment of Very High Triglycerides (VHTG)
-First and Only FDA Approved Pure-EPA Omega-3 Prescription Therapy Now Available- -Vascepa Reduces VHTG Without Raising LDL Cholesterol- BEDMINSTER, N.J., and DUBLIN, Ireland, Jan. 24, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company fo
Read more →AMRNAmarin Announces First Notification of U.S. Patent Allowance Based on ANCHOR Clinical Trial Results
BEDMINSTER, N.J. and DUBLIN, Ireland, Jan. 23, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the United States Pate
Read more →AMRNAmarin Announces Publication of Additional Inflammatory Marker Data From MARINE and ANCHOR Phase 3 Clinical Trials in the American Journal of Cardiovascular Drugs
BEDMINSTER, N.J. and DUBLIN, Ireland, Jan. 22, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that additional data from i
Read more →AMRNAmarin Announces Notification of Patent Allowance for U.S. Application 13/610,217 Related to Vascepa(R) and FDA Approved MARINE Indication
BEDMINSTER, N.J., and DUBLIN, Ireland, Jan. 11, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the United States Pat
Read more →AMRNAmarin Announces Submission of a Supplemental New Drug Application for BASF as Additional Vascepa(R) Active Pharmaceutical Ingredient Supplier
BEDMINSTER, N.J. and DUBLIN, Ireland, Jan. 2, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today the late December 2012 submi
Read more →AMRNAmarin to Present at the 31st Annual J.P. Morgan Healthcare Conference
BEDMINSTER, N.J., and DUBLIN, Ireland, Jan. 2, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced that Joseph Zakrzewski, Amarin's
Read more →AMRNAmarin Announces Submission of Supplemental New Drug Application for Chemport, Inc. as an Additional Vascepa(R) Active Pharmaceutical Ingredient Supplier
BEDMINSTER, N.J. and DUBLIN, Ireland, Dec. 19, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today the submission of a Supplem
Read more →AMRNAmarin Announces Completion of Dosing in a Fixed-Dose Combination Study With Vascepa(R) and a Leading Statin
BEDMINSTER, N.J., and DUBLIN, Ireland, Dec. 17, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that it has completed dosi
Read more →AMRNAmarin Announces Notification of Patent Allowance for U.S. Application 13/623,450 Related to Vascepa(R) and FDA Approved MARINE Indication
BEDMINSTER, N.J., and DUBLIN, Ireland, Dec. 13, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the United States Pat
Read more →AMRNAmarin Announces Additional Vascepa(R) (icosapent ethyl) Supplier
BEDMINSTER, N.J. and DUBLIN, Ireland, Dec. 11, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the development of therapeutics to improve cardiovascular health, today announced the addition of an exclusive consortium of compan
Read more →AMRNAmarin Announces $100 Million Non-Equity Financing and Vascepa Sales Force Hiring while Continuing to Assess Strategic Alternatives - Steps Are Consistent with Amarin s Continuation of Its Strategy to Parallel Process Th
Amarin Announces $100 Million Non-Equity Financing and Vascepa Sales Force Hiring while Continuing to Assess Strategic Alternatives - Steps Are Consistent with Amarin s Continuation of Its Strategy to Parallel Process Three Strategic Options- -Conference Call Scheduled for To
Read more →AMRNAmarin Announces U.S. Patent 8,324,195 Issuance for Vascepa(R)
BEDMINSTER, N.J. and DUBLIN, Ireland, Dec. 4, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the U.S. Patent and Tra
Read more →AMRNAmarin Announces U.S. Patent 8,318,715 Issuance for Vascepa(R)
BEDMINSTER, N.J. and DUBLIN, Ireland, Nov. 27, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the U.S. Patent and Tr
Read more →AMRNAmarin Announces Notification of Patent Allowance for U.S. Application 13/610,247 Related to Vascepa(R) and FDA Approved MARINE Indication
BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 26, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the United States Pat
Read more →AMRNAmarin Announces U.S. Patent 8,314,086 Issuance for Vascepa(R)
BEDMINSTER, N.J. and DUBLIN, Ireland, Nov. 20, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the U.S. Patent and Tr
Read more →AMRNAmarin Announces Notification of Patent Allowance for U.S. Application 13/608,775 Related to Vascepa(R) and FDA Approved MARINE Indication
BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 19, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the United States Pat
Read more →AMRNAmarin Reports Third Quarter 2012 Financial Results and Provides Update on Operations - Conference Call Set for 4:30 p.m. EST Today - BEDMINSTER, N.J., and
Amarin Reports Third Quarter 2012 Financial Results and Provides Update on Operations - Conference Call Set for 4:30 p.m. EST Today - BEDMINSTER, N.J., and DUBLIN, Ireland, November 8, 2012 Amarin Corporation plc (Nasdaq: AMRN), a biopharmaceutical company focused on the comm
Read more →AMRNAmarin to Report Third Quarter 2012 Financial Results and Host Conference Call on November 8, 2012
BEDMINSTER, N.J. and DUBLIN, Ireland, Nov. 1, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that it will host a conferen
Read more →AMRNAmarin Announces U.S. Patent 8,298,554 Issuance for Vascepa(TM)
BEDMINSTER, N.J. and DUBLIN, Ireland, Oct. 30, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the U.S. Patent and Tr
Read more →AMRNAmarin Announces Issuance of U.S. Patents 8,793,727 and 8,293,728 for Vascepa(TM)
BEDMINSTER, N.J. and DUBLIN, Ireland, Oct. 23, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the U.S. Patent and Tr
Read more →AMRNAmarin Announces Notification of Patent Allowance for U.S. Application 13/349,150 Related to Vascepa(TM) and FDA Approved MARINE Indication
BEDMINSTER, N.J., and DUBLIN, Ireland, Sept. 10, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the United States Pa
Read more →AMRNAmarin Announces Notification of Patent Allowance for U.S. Application 13/284,408 Related to Vascepa(TM) and FDA Approved MARINE Indication
BEDMINSTER, N.J., and DUBLIN, Ireland, Sept. 6, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the United States Pat
Read more →AMRNAmarin Announces Notification of Patent Allowances for U.S. Applications 12/702,889 and 13/349,153 Related to Vascepa(TM) and FDA Approved MARINE Indication
BEDMINSTER, N.J., and DUBLIN, Ireland, Sept. 5, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the United States Pat
Read more →AMRNAmarin Announces Notification of Patent Allowance for U.S. Application 13/282,145 Related to Vascepa(TM) and FDA Approved MARINE Indication
BEDMINSTER, N.J. and DUBLIN, Ireland, Sept. 4, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the United States Pate
Read more →AMRNAmarin Announces Additional Publication of MARINE Phase 3 Clinical Trial Results in the Journal of Clinical Lipidology
Reductions in Lipoprotein Particle Concentration Shown in Patients With Severe ( 500 mg/dL) Hypertriglyceridemia BEDMINSTER, N.J., and DUBLIN, Ireland, Aug. 28, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercializ
Read more →AMRNAmarin Reports Second Quarter 2012 Financial Results and Provides Update on Operations - Conference Call Set for 4:30 p.m. EDT Today - BEDMINSTER, N.J., and
Amarin Reports Second Quarter 2012 Financial Results and Provides Update on Operations - Conference Call Set for 4:30 p.m. EDT Today - BEDMINSTER, N.J., and DUBLIN, Ireland, August 8, 2012 Amarin Corporation plc (Nasdaq: AMRN), a biopharmaceutical company focused on the comme
Read more →AMRNAmarin to Report Second Quarter 2012 Financial Results and Host Conference Call on August 8, 2012
BEDMINSTER, N.J. and DUBLIN, Ireland, July 31, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that it will host a confere
Read more →AMRNAmarin Announces FDA Approval of Vascepa (icosapent ethyl) Capsules for the Reduction of Triglyceride Levels in Adult Patients with Severe (TG 500 mg/dL) Hypertriglyceridemia -Approval Based on Positive Results from MARI
Amarin Announces FDA Approval of Vascepa (icosapent ethyl) Capsules for the Reduction of Triglyceride Levels in Adult Patients with Severe (TG >500 mg/dL) Hypertriglyceridemia -Approval Based on Positive Results from MARINE Study- -Conference Call Scheduled for Today, July 26
Read more →AMRNAmarin Announces FDA Approval of Vascepa(TM) (icosapent ethyl) Capsules for the Reduction of Triglyceride Levels in Adult Patients With Severe Hypertriglyceridemia
Approval Based on Positive Results From MARINE Study Conference Call Scheduled for Today, July 26th at 7:00 p.m. EDT BEDMINSTER, N.J. and DUBLIN, Ireland, July 26, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commerci
Read more →AMRNAmarin Receives Notice of Intention to Grant on European Patent
BEDMINSTER, N.J. and DUBLIN, Ireland, July 25, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company focused on the development of therapeutics to improve cardiovascular health, announced today that the European Patent Office has is
Read more →AMRNAmarin Announces Publication of ANCHOR Phase 3 Clinical Trial Results in The American Journal of Cardiology
BEDMINSTER, N.J., and DUBLIN, Ireland, July 24, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company focused on cardiovascular disease, announced today that the results of its pivotal ANCHOR Phase 3 clinical trial are now available
Read more →AMRNAmarin Announces Notice of Allowance for Additional U.S. Patent Covering AMR101
BEDMINSTER, N.J., and DUBLIN, Ireland, July 2, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company focused on cardiovascular disease, announced today that the United States Patent and Trademark Office (USPTO) has published notific
Read more →AMRNAmarin to Present at the Jefferies 2012 Global Healthcare Conference
BEDMINSTER, N.J. and DUBLIN, Ireland, May 29, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that John F. Thero, Amarin's President, is scheduled to present a general co
Read more →AMRNAmarin Announces U.S. Patent Issuance for AMR101
BEDMINSTER, N.J. and DUBLIN, Ireland, May 29, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company focused on cardiovascular disease, announced today that the U.S. Patent and Trademark Office (USPTO) has issued a patent covering th
Read more →AMRNAmarin Reports First Quarter 2012 Financial Results and Provides Update on Operations - Conference Call Set for 4:30 p.m. EDT Today - BEDMINSTER, N.J., and
Amarin Reports First Quarter 2012 Financial Results and Provides Update on Operations - Conference Call Set for 4:30 p.m. EDT Today - BEDMINSTER, N.J., and DUBLIN, Ireland, May 8, 2012 Amarin Corporation plc (Nasdaq: AMRN), a late-stage biopharmaceutical company focused on ca
Read more →AMRNAmarin to Report First Quarter 2012 Financial Results and Host Conference Call on May 8, 2012
BEDMINSTER, N.J. and DUBLIN, Ireland, May 1, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company focused on cardiovascular disease, announced today that it will host a conference call with members of Amarin senior management to di
Read more →AMRNAmarin Announces Notification of Patent Allowance for AMR101
BEDMINSTER, N.J. and DUBLIN, Ireland, March 20, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company with a focus on cardiovascular disease, announced today that the United States Patent and Trademark Office (USPTO) has published n
Read more →AMRNAmarin to Present at the 24th Annual ROTH OC Growth Stock Conference
BEDMINSTER, N.J. and DUBLIN, Ireland, March 6, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that Amarin management is scheduled to present a corporate overview and gen
Read more →AMRNAmarin Reports Fourth Quarter and Year-End 2011 Financial Results and Provides Update on Operations - Conference Call Set for 4:30 p.m. EST Today - BEDMINSTER, N.J., and
Amarin Reports Fourth Quarter and Year-End 2011 Financial Results and Provides Update on Operations - Conference Call Set for 4:30 p.m. EST Today - BEDMINSTER, N.J., and DUBLIN, Ireland, Feb. 29, 2012 Amarin Corporation plc (Nasdaq: AMRN), a late-stage biopharmaceutical compa
Read more →AMRNAmarin to Present at the CITI 2012 Global Healthcare Conference
BEDMINSTER, N.J. and DUBLIN, Ireland, Feb. 22, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that Joseph S. Zakrzewski, Amarin's Chairman and Chief Executive Officer, i
Read more →AMRNAmarin to Report Fourth Quarter and Year-End 2011 Results and Host Conference Call on February 29, 2012
BEDMINSTER, N.J. and DUBLIN, Ireland, Feb. 22, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company focused on cardiovascular disease, announced today that it will host a conference call with members of Amarin senior management to
Read more →AMRNAmarin Corporation Appoints Dr. Steven Ketchum to Head Research and Development and Announces Inducement Grant Under NASDAQ Rule 5635(c)(4) BEDMINSTER, N.J., and
Amarin Corporation Appoints Dr. Steven Ketchum to Head Research and Development and Announces Inducement Grant Under NASDAQ Rule 5635(c)(4) BEDMINSTER, N.J., and DUBLIN, Ireland, Feb. 16, 2012 Amarin Corporation plc (Nasdaq: AMRN), a late-stage biopharmaceutical company with a
Read more →AMRNAmarin Announces FDA Advisory Committee Will Not Be Scheduled in Connection With New Drug Application for AMR101
BEDMINSTER, N.J. and DUBLIN, Ireland, Feb. 13, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company with a focus on cardiovascular disease, announced today that it was informed by the U.S. Food and Drug Administration (FDA) that no
Read more →AMRNAmarin to Present at the Leerink Swann 2012 Global Healthcare Conference
BEDMINSTER, N.J. and DUBLIN, Ireland, Feb. 7, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company with a focus on cardiovascular disease today announced that John F. Thero, Amarin's President, is scheduled to present at the Leerin
Read more →AMRNAmarin Corporation plc Announces Pricing of $150 Million of Exchangeable Senior Notes Due 2032
BEDMINSTER, N.J. and DUBLIN, Ireland, Jan. 4, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN) announced today that its wholly owned subsidiary, Corsicanto Limited, a private limited company incorporated under the laws of Ireland (the "Issuer"), priced its previously
Read more →AMRNAmarin Commences 2012 with Letter to Shareholders -2012 Priorities Outlined- BEDMINSTER, N.J., and
Amarin Commences 2012 with Letter to Shareholders -2012 Priorities Outlined- BEDMINSTER, N.J., and DUBLIN, Ireland, Jan. 3, 2012 Amarin Corporation plc (NASDAQ: AMRN), a late-stage biopharmaceutical company with a focus on cardiovascular disease, today issued its annual letter
Read more →AMRNAmarin Corporation plc Announces Offering of $150 million of Exchangeable Senior Notes due 2032 BEDMINSTER, N.J., and
Amarin Corporation plc Announces Offering of $150 million of Exchangeable Senior Notes due 2032 BEDMINSTER, N.J., and DUBLIN, Ireland, January 3, 2012 Amarin Corporation plc (Nasdaq:AMRN) announced today that its wholly owned subsidiary, Corsicanto Limited, a private limited c
Read more →AMRNAmarin Commences 2012 With Letter to Shareholders
BEDMINSTER, N.J., and DUBLIN, Ireland, Jan. 3, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company with a focus on cardiovascular disease, today issued its annual letter to shareholders. The text of this letter, written by Joseph
Read more →AMRNAmarin Announces Appointment of Joseph T. Kennedy as General Counsel and Issuance of Inducement Grant Under NASDAQ Rule 5635(c)(4)
BEDMINSTER, N.J., and DUBLIN, Ireland, Dec. 19, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company with a focus on cardiovascular disease, today announced the appointment of Joseph T. Kennedy to the newly created position of Seni
Read more →AMRNAmarin Announces the Addition of Industry Veteran Patrick O'Sullivan to Board
BEDMINSTER, N.J. and DUBLIN, Ireland, Dec. 14, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that Patrick "Paddy" O'Sullivan has joined the Board of Directors as an ind
Read more →AMRNAmarin Announces Dosing of First Patient in Cardiovascular Outcomes Study REDUCE-IT
BEDMINSTER, N.J., and DUBLIN, Ireland, Dec. 7, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company with a focus on cardiovascular disease, today announced the dosing of the first patient in REDUCE-IT, the cardiovascular outcomes s
Read more →AMRNAmarin Announces FDA Acceptance for Filing of AMR101 NDA
BEDMINSTER, N.J. and DUBLIN, Ireland, Nov. 25, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company focused on cardiovascular disease, today announced that its New Drug Application (NDA) for AMR101 has been accepted for filing by t
Read more →AMRNAmarin Announces Resignation of David Feigal from Board of Directors
BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 25, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company focused on cardiovascular disease, today announced that Dr. David Feigal has resigned as a member of the Company's Board of Direct
Read more →AMRNAmarin Added to NASDAQ Biotechnology Index
BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 21, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company focused on cardiovascular disease, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasda
Read more →AMRNAmarin's Phase 3 ANCHOR Study Results Presented at American Heart Association's Scientific Sessions 2011
BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 16, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company with a focus on cardiovascular disease, announced today the first presentation in a scientific session of data from Amarin's Phase
Read more →AMRNAmarin's Phase 3 MARINE Study Results Presented at American Heart Association's Scientific Sessions 2011
BEDMINSTER, N.J. and DUBLIN, Ireland, Nov. 15, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company with a focus on cardiovascular disease, today announced the presentation of data from Amarin's Phase 3 clinical trial, the MARINE s
Read more →AMRNAmarin's Phase 3 MARINE and ANCHOR Study Data to be Presented at American Heart Association's Scientific Sessions 2011
BEDMINSTER, N.J. and DUBLIN, Ireland, Nov. 14, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company with a focus on cardiovascular disease, announced that data from each of its two pivotal Phase 3 studies, the ANCHOR trial and the
Read more →AMRNAmarin Reports Third Quarter 2011 Results
BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 7, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company focused on cardiovascular disease, today reported financial and operating results for the quarter ended September 30, 2011 (Q3
Read more →AMRNAmarin Announces Q3, 2011 Results Conference Call
BEDMINSTER, N.J. and DUBLIN, Ireland, Nov. 3, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company focused on cardiovascular disease, has scheduled a conference call with members of senior management to discuss the Company's fi
Read more →AMRNAmarin Corporation PLC (AMRN) to Ring The NASDAQ Stock Market Closing Bell
ADVISORY, Nov. 1, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation PLC (AMRN), a prominent biopharmaceutical company with expertise in lipid science focused on the treatment of cardiovascular disease, will visit the NASDAQ MarketSite in New York City's Times Square in recognition of
Read more →AMRNAmarin to Ring NASDAQ Closing Bell
BEDMINSTER, N.J. and DUBLIN, Ireland, Oct. 31, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that Joseph Zakrzewski, Amarin's Chairman and CEO, has been invited to
Read more →AMRNAmarin Announces NDA Submission for AMR101 for the Treatment of Patients With Very High Triglycerides
BEDMINSTER, N.J. and DUBLIN, Ireland, Sept. 26, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food an
Read more →AMRNAmarin to Present at the UBS Global Life Sciences Conference
BEDMINSTER, N.J. and DUBLIN, Ireland, Sept. 19, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that Joseph Zakrzewski, Amarin's Executive Chairman and Chief Executiv
Read more →AMRNAmarin Announces Successful MARINE Phase 3 Clinical Trial Results Published in The American Journal of Cardiology
BEDMINSTER, N.J., and DUBLIN, Ireland, Sept. 1, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that results of its pivotal MARINE Phase 3 clinical trial were publish
Read more →AMRNAmarin to Present at the Wedbush Securities Life Sciences Management Access Conference
MYSTIC, Conn. and DUBLIN, Ireland, Aug. 12, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that Joseph Zakrzewski, Amarin's Executive Chairman and Chief Executive Of
Read more →AMRNAmarin Announces Agreement From FDA on Special Protocol Assessment for AMR101 Outcomes Study
MYSTIC, Conn. and DUBLIN, Ireland, Aug. 10, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that it has reached agreement with the U.S. Food and Drug Administration (
Read more →AMRNAmarin Reports Second Quarter 2011 Results
- Company on Track for NDA Filing This Quarter - - Conference Call Set for 8:00 am EDT August 10 - MYSTIC, Conn. and DUBLIN, Aug. 9, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company focused on cardiovascular disease, toda
Read more →AMRNAmarin to Present at the 2011 Canaccord Genuity Growth Conference
MYSTIC, Conn. and DUBLIN, Aug. 8, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that John Thero, Amarin's President, will present at the 2011 Canaccord Genuity Grow
Read more →AMRNAmarin Announces Q2, 2011 Results Conference Call
MYSTIC, Conn. and DUBLIN, Aug. 8, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company focused on cardiovascular disease, has scheduled a conference call with members of senior management to discuss the Company's financial resu
Read more →AMRNAmarin Successfully Completes All Remaining Clinical Studies for AMR101 NDA
MYSTIC, Conn. and DUBLIN, Ireland, Aug. 1, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, announced today the successful completion of all remaining studies required for the Company
Read more →AMRNAmarin Completes All Non-Clinical Work for AMR101 NDA Submission
MYSTIC, Conn. and DUBLIN, July 7, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, announced today the successful completion of the remaining non-clinical studies for the Company's pl
Read more →AMRNAmarin to Present at the Jefferies 2011 Global Healthcare Conference
MYSTIC, Conn. and DUBLIN, Ireland, June 1, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that Joseph Zakrzewski, Amarin's Executive Chairman and Chief Executive Off
Read more →AMRNAmarin Announces Global Supply Network for AMR101
MYSTIC, Conn. and DUBLIN, May 31, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, announced today the expansion of its capability to supply AMR101 through the addition of two active
Read more →AMRNAmarin-Sponsored Posters to be Presented Today at the National Lipid Association 2011 Annual Scientific Sessions
-EPA Therapy Demonstrates a Wide Range of Lipid Lowering Benefits Without the LDL-C Increase as Seen With Omega-3s Containing DHA- -Amarin's AMR101 Contains >96% EPA- NEW YORK, May 19, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceu
Read more →Competitive Position
How AMRN ranks across every disease it competes inCompetitive Position is a premium feature
See how AMRN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial